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Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory 
lung disease that causes obstructed airflow from the lungs. Nowadays, COPD is 
the fourth leading cause of death in the world and its morbidity and mortality 
are constantly increasing. COPD is characterized by emphysema and chronic 
bronchitis, usually present simultaneously, with a wide range of severity. COPD 
was considered as a lung-restricted disease for many years, but from 2000 
increasing new evidence, including a number of comorbid conditions 
accompanying this pathology and the presence of systemic inflammation, 
indicate that COPD should be considered a systemic disease. Systemic 
inflammation is the most common systemic manifestation of COPD, and it is 
associated with a progressive worsening of symptoms and comorbidities. In 
addition to soluble inflammatory markers, such as TNFα, several research 
groups focused their attention on peripheral blood leukocytes to assess the 
changes occurring in these cells in COPD and their relation to the inflammatory 
pattern in the lungs. However, the data about peripheral leukocyte composition 
and functional changes in COPD are quite controversial. 
COPD was traditionally considered as a disease affecting principally males, 
but rising evidence show that it probably equally concerns male and female 
populations. However, there are differences in symptoms severity, disease 
progression and treatment benefits between male and female COPD. Yet, 
despite the clear evidence of sexual dimorphism in COPD manifestation and 
progression, there are, to our knowledge, no publications about the difference 
in the immune state between male and female COPD. 
Given the lack of data assessing gender-related differences in COPD systemic 
immune system manifestations and the discordance in the data about 
circulating leukocyte alterations in COPD, we aimed at thoroughly characterize 
circulating leukocyte alterations in COPD as compared to age-matched controls. 
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Additionally, results have been stratified according to gender in order to 
identify male- and/or female-specific COPD immunophenotype. 
Blood samples from 50 COPD patients and 63 age and sex-matched controls 
have been collected and analyzed. Flow cytometry analysis revealed the 
existence of well-defined gender-related pattern of circulating leukocytes in 
COPD. Specifically, while neutrophilia and increased neutrophil to lymphocyte 
ratio are hallmarks of COPD in male, on the contrary, female COPD are 
characterized by a generalized leukopenia. Remarkably, we demonstrated that 
T cell exhaustion is more prominent in female COPD, nevertheless it increases 
with disease severity in both male and female groups. Moreover, several 
observations suggest that that T cells decrease in both male and female COPD 
may be related to PD1-dependent apoptosis. Additionally, we showed that 
absolute numbers and/or frequencies of several leukocyte populations 
correlate with different clinical parameters of COPD disease severity. 
Given the relevance of the increase in neutrophil absolute count and 
frequency in male COPD, we subsequently characterized circulating neutrophil 
phenotype, function and transcriptome of male COPD and related controls.  
Despite the fact that phenotype and function of neutrophils purified from COPD 
subjects were comparable to those from controls, differential gene expression 
analysis highlighted a number of differentially expressed genes. On the basis of 
the correlation of the differentially expressed genes with the disease severity, 
we identified a neutrophil-specific COPD signature. Finally, this proposed COPD 
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ANOVA – analysis of variance 
APC – allophycocyanin 
BAFF – B cell-activating factor belonging to the TNF family 
BAL – bronchoalveolar lavage 
BMI – body mass index 
BrDU – bromodeoxyuridine 
CCR – CC-chemokine receptor 
COPD – chronic obstructive pulmonary disease 
CRP – C-reactive protein 
CT – computerized tomography 
CTL – cytotoxic T-lymphocytes 
CVD – cardiovascular diseases  
CXCR – CXC-chemokine receptor 
DC – dendritic cells 
DLCO – diffusing capacity of the lungs for carbon monoxide 
ECLIPSE – evaluation of COPD longitudinally to identify predictive 
surrogate endpoints 
EDTA – ethylenediamine tetra-acetic acid 
ERV – expiratory reserve volume 
FACS – fluorescense-activated cell sorting method 
FBS – fetal bovine serum 
FEV1 – forced expiratory volume in 1 second  
FITC – fluorescein isothiocyanate 
fMLP – formyl-methionyl-leucyl phenylalanine 
FPKM – fragments per kilobase of transcript per million mapped reads		
FSC – forward scatter 
FVC – forced vital capacity 
7 
 
GO – gene ontology 
GOLD – Global Initiative for Obstructive Lung Disease COPD grade units 
GTPase – guanosine triphosphatase 
HBSS – Hank’s balanced salt solution 
HLA-DR – major histocompatibility complex class II 
IC – inspiratory capacity  
IL – interleukin 
KCO – carbon monoxide transfer coefficient 
LPS – lipopolysaccharide 
LRT – likelihood ratio test  
MDSC – myeloid-derived suppressor cells 
MMEF – mean mid-expiratory flow  
MMP – matrix metalloproteinase  
MPO – myeloperoxidase  
MRC – Medical Research Council scale 
mRNA – messenger RNA 
NE – neutrophil elastase  
NK – natural killer cells 
NKT – natural killer T cells 
NLR – neutrophil-to-lymphocyte ratio  
O2·− – superoxide anion 
PBMC – peripheral blood mononuclear cells 
PBS – phosphate buffer salt 
PC – principal component 
PCA – principal component analysis 
PD1– programmed cell death 1 
PDL1 – programmed cell death ligand 1 
PE – phycoerythrin 
PerCP – peridinin chlorophyll protein 
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PMA – phorbol myristate acetate 
PMN – polymorphonuclear neutrophils 
RNA – ribonucleic acid 
ROS – reactive oxygen species  
RPMI – Roswell Park Memorial Institute medium 
RV – residual volume  
SD – standard deviation 
TCM – central memory T cells  
TEM – effector memory T cells  
TEMRA – effector memory CD45RA+ T cells  
Th – T helper cells 
TLC – total lung capacity  
TNFα – tumor necrosis factor alpha 
Treg – T regulatory cells 
UMI – Unique Molecular Indices  







Chronic obstructive pulmonary disease, or COPD, refers to a group of 
diseases characterized by progressive airflow obstruction and shortness of 
breath. At the lung level, COPD is manifested in chronic bronchitis, bronchiolitis 
(small airway disease), and emphysema.  According to the recent report of the 
World Health Organization, COPD is the fourth leading cause of death in the 
world. The most common reason for COPD development is smoking. However, 
the results of a 25-years follow-up study revealed that only about 25% of 
continuous smokers develop COPD in 25 years (Løkke et al. 2006) and the 
reason why some smokers develop COPD and the others do not is still 
unknown. Air pollution and exposure to biomass smoke, such as using biomass 
fuel for heating and cooking, are the other important risk factors, significantly 
associated with COPD development. There is also a genetic component in COPD. 
The most known genetic factor of COPD development is an α1-antitrypsin 
deficiency – a rare condition that affects about 1:2000 to 1:5000 individuals 
and frequently leads to progressive lung emphysema (Stoller and Aboussouan 
2012). There are also several other genetic mutations that were associated with 
an increased risk of COPD development (Hobbs and Hersh 2014). 
The disease pathophysiology includes inflammation in small and large 
airways, usually provoked by cigarette smoke particles or other airborne 
irritators, that leads to airway walls thickening, mucus hypersecretion and 
mucous metaplasia – the hallmarks of chronic bronchitis. Massive immune 
response and other factors, including uncontrolled trypsin or other enzymes 
activity due to  genetic defects in protease balance (Brode, Ling, and Chapman 
2012), cause the destruction of alveolar walls that leads to the development of 
emphysema.  Most people with COPD have both emphysema and chronic 
bronchitis, but the prevalence and severity of each condition vary from person 
to person  (Bhat et al. 2015).  
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The degree of COPD severity can be estimated by different means:  
I. COPD severity is evaluated on the basis of self-assessed symptoms and 
some generic physical activity measurements, such as a 6-minute walking 
test. Self-assessed COPD symptoms include cough intensity (usually on a 
scale from 0 to 10), sputum production (usually reported in 
tablespoons/day), and dyspnea grade (usually reported as MRC score 
from 0 to 4). Questionnaires and self-assessed symptom severity scales are 
very variable, as the same person can give different answers to the 
question in slightly different conditions.  
II. The most precise COPD severity assessment method is a computerized 
tomography (CT) scan, that can provide objective information about 
emphysema grade, chronic bronchitis severity (airway walls thickness) 
and, with some limitations, bronchiolitis (Segal and Martinez 2018). 
However, a CT scan is not widely used for COPD patients as it is an 
expensive procedure.  
III. The easiest and most used method to assess COPD severity is spirometry 
test, which gives information about the patient’s breathing capacity. The 
spirometry test includes static and dynamic lung volumes measurements. 
Static lung volumes refer to the lung size and elasticity and include 
inspiratory capacity (IC) – the amount of air that can be inhaled after the 
end of a normal expiration, total lung capacity (TLC) – the volume in the 
lungs at maximal inflation, and residual volume (RV) – the volume of air 
remaining in the lungs after a maximal exhalation (Figure 1).  
The main reason for the alteration of the static lung volumes in COPD is lung 
hyperinflation that occurs in most COPD patients. Both static and dynamic lung 
hyperinflation may take place. Static hyperinflation is a feature of severe 
emphysematous patients and is caused by lung elasticity loss. Dynamic lung 
hyperinflation is very common and is attributed to air trapping, which is caused 
by too slow exhalation due to airway obstruction. Unlike static hyperinflation, 
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which can be easily estimated by IC/TLC or RV/TLC alterations, dynamic 
hyperinflation requires specific additional tests (Shin et al. 2015). Although 
dynamic hyperinflation has been considered a major contributor to reduced 
quality of life and poor exercise capacity in COPD (Krieger 2009), static 
hyperinflation, as expressed by IC/TLC or RV/TLC, was reported to be an 
independent predictor of mortality in COPD (Casanova et al. 2005; Budweiser 
et al. 2014; Shin et al. 2015). 
 
Figure 1. Static lung volumes (Lutfi 2017) 
 
Alterations of dynamic lung volumes (Figure 2) is a direct consequence of 
airway obstruction, as narrowed bronchial lumen limits the speed of 
exhalation. The most important spirometric parameter for COPD severity 
assessment is the forced expiratory volume in 1 second (FEV1) – the maximal 
volume of air that can be forcefully exhaled in 1 second. This parameter varies 
from person to person and depends on sex, age height, weight, and race. 
Therefore, it is usually substituted by normalized value, expressed as a percent 
of predicted values for the subject of the same age, sex, and body composition 
(FEV1%). FEV1% continuously declines with COPD progression as airway 
12 
 
obstruction raises. Another important severity indicator is FEV1/FVC – a ratio 
between FEV1 and forced vital capacity (total volume of air that can be possibly 
forcefully exhaled). FVC also declines with COPD progression, but not as much 
as FEV1, which leads to a decrease of FEV1/FVC. This phenomenon helps to 
distinguish COPD from restrictive lung diseases, such as lung fibrosis, where 
FEV1 and FVC decline at the same levels, leading to low FEV1%, but stable 
FEV1/FVC ratio.  FEV1/FVC ratio is widely used as a diagnostic tool with an 
established cutoff of 0.7. People with FEV1/ FVC < 0.7 are considered to have 
COPD. Additional information that can be obtained by spirometry is an 
exhalation flowrate. The mean flow rate of 25% and 75% of total air exhaled is 
called mean mid-expiratory flow (MMEF) and can indicate the presence of 
small airway disease (Estenne et al. 2002).  To distinguish COPD from asthma, 
another obstructive lung disease with prevalently allergic etiology, all 
spirometry measurements are conducted after bronchodilator use. Unlike 
asthma, that can be generally kept under control with the use of 
bronchodilators, in COPD expiratory parameters, such as FEV1, FEV1/FVC 
ratio, and MMEF, can be poorly restored after bronchodilators use. This 





Figure 2. Dynamic lung volumes. Adapted from Mhetre et al. (Mhetre, Patil, 
and Abhyankar 2018) 
 
FEV1% is used as the main parameter to define the severity of COPD. 
According to Global Initiative for Obstructive Lung Disease (GOLD) COPD 
severity can be defined as MILD (FEV1% ≥ 80%), MODERATE (50% ≤ FEV1% 
<80%), SEVERE (30% ≤ FEV1% < 50%), and VERY SEVERE (FEV1% < 30%) 
(Hadfield 2017). However, severity classification based only on FEV1% value is 
incomplete and does not consider pathophysiologic derangements and 
possible histopathologic conditions that lead to airway obstruction, as well as 
the other important features, such as symptoms (as wheeze and dyspnea), 
physical capacity (6-min walking distance and quadriceps maximum voluntary 
contraction), and exacerbation risk, that all remain very important for 
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prognosis and the choice of treatment strategy (Segal and Martinez 2018). This 
is the reason why researchers and physicians are still in search for a better 
COPD assessment. From the 2011 GOLD organization updated COPD 
assessment guide introducing A-D groups, defined according to dyspnea score 
(MRC) and the number and the severity of exacerbations in the previous year. 
Nevertheless,   effective guidelines for COPD assessment are still lacking (Segal 
and Martinez 2018). 
COPD	heterogeneity	and	patients’	phenotyping	
As COPD is defined just as spirometry-based identification of airway 
obstruction, it is not surprising that this pathology is highly heterogeneous. 
Indeed, emphysema prevalent and chronic bronchitis prevalent are not the 
only phenotypes that can be distinguished within COPD. There is also Asthma-
COPD overlap phenotype that combines features of both obstructive diseases 
and is characterized by higher symptom severity and poorer prognosis, 
genetically determined α1-antitrypsin deficiency-related phenotype, very 
distinct from the other COPD by early onset and trypsin-dependent lung tissue 
destruction, eosinophilic COPD, characterized by high blood eosinophil count 
and massive eosinophils infiltration into lungs during exacerbations (Segal and 
Martinez 2018) and possibly some others. 
The benefit of different treatment approaches is not equal in these 
phenotypes.   
COPD	systemic	features	
COPD was considered as a lung-restricted disease for many years, but from 
2000 to nowadays some new evidence of its systemic manifestations has been 
provided. This includes a number of comorbid conditions accompanying this 
pathology. These comorbidities can be divided into three main groups. First – 
the ones directly related to lung function impairment, such as cardiovascular 
diseases and erythrocyte abnormalities: ischemic heart disease, ventricular 
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failure, and normocytic anemia.  The second group – diseases related to lung 
immunity disruption: lung infections and lung cancer. The third group includes 
the diseases, which are not directly related to COPD pathology development, 
but frequently appear in COPD patients: diabetes, metabolic syndrome, muscle 
weakness, depression, osteoporosis (A. G. N. Agustí et al. 2003; Huertas and 
Palange 2011; P. J. Barnes and Celli 2009). Recent publications refer to systemic 
inflammation as one of the most common COPD systemic manifestations, that 
is also linked to worsening of the symptoms and comorbidities progression 
(Austin et al. 2016; A. Agustí et al. 2012).   The main aspects of local and 




Inflammatory response in the lungs, usually related to lung tissue irritation 
by cigarette smoke particles or other inhaled compounds, is known to play the 
major pathological role in COPD progression. This includes, on the first place, 
neutrophil infiltration and massive matrix metalloproteinases (MMPs), 
myeloperoxidase (MPO) and reactive oxygen species (ROS) production by 
these cells, that cause direct destruction of lung tissue, and T cells 
(predominantly CD8+ CTL) migration to the lungs, where they perform 
cytotoxic activity (Peter J Barnes and Cosio 2004). New studies also include B 
cells as key players in COPD pathology, demonstrating that they not only 
infiltrate the lungs of COPD patients, but also form lymphoid follicles along the 
airways, which number correlates with poor prognosis (Hogg et al. 2004; 






In a detailed review of the last year Dong et al (Dong et al. 2020) summarized 
what is known about inflammatory markers in sputum of COPD patients. Brief 
results of their investigation are presented below and are summarized 
in the Table 1.  
Many authors report an increase of CRP level in the sputum, which also 
correlates with the lung function impairment and with the amount of 
produced sputum.  
Among interleukins both IL-6 and IL-8 levels were shown to be elevated in 
COPD patients in comparison to controls, independently of the smoking habit, and 
their concentrations correlated inversely with FEV1%. Other studies also 
demonstrated a direct correlation of both IL-6 and IL-8 with FEV1% decline 
speed.  IL-6 level was also able to distinguish between COPD and asthma patients. 
Several authors have reported an increased MMP-8 and MMP-9 activity in 
COPD-derived sputum. For MMP-9 the correlation with COPD severity was 
also shown. 
TNFα was also shown to be increased in the sputum of COPD patients and to 
correlate with the disease progression. However, in two different studies was 
shown no significant difference between healthy smokers and non-smokers 
and no significant difference between healthy smokers and COPD, respectively. 
As well as other agents secreted by activated neutrophils, neutrophil elastase 
(NE) level is increased in COPD induced sputum. It also was shown to correlate 






Table 1. Protein biomarkers in the sputum of COPD patients 
Molecule	 Change	in	sputum Additional	observations 
CRP Increased 
concentration 
• Correlates with the lung function 




• Is elevated independently of the smoking 
habit 
• Correlates inversely with FEV1% 
• Correlates with FEV1% decline speed 




• Is elevated independently of the smoking 
habit 
• Correlates inversely with FEV1% 






• Correlates with COPD severity 
TNFα Increased 
concentration 
• Correlates with COPD severity 
• Some authors report no difference 
between COPD and healthy smokers 
Neutrophil elastase (NE) Increased 
concentration 
• Correlates with COPD severity 




The role of systemic inflammation in COPD pathology and the reflection of 
the immune process occurring in the lungs on peripheral blood level are now 
actively being studied. In particular, it has been suggested that cellular and 
transcriptomic changes in the lung parenchyma may be reflected in peripheral 
blood (Teresa and Bhat 2013; Faner et al. 2019). However, it is unclear if 
systemic inflammation is secondary to local lung inflammation and occurs as a 
consequence of inflammatory cytokines hypersecretion in the lungs, or 
systemic inflammation develops independently due to other diseases or 
conditions and can potentiate COPD development in susceptible subjects 
(Sevenoaks and Stockley 2006; Peter J. Barnes 2016). 
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Several inflammatory markers were found to be elevated in the blood of 
COPD patients.  Serum levels of C-reactive protein was found elevated in COPD, 
both in the acute and stable phase (İn et al. 2016; W. Q. Gan 2004; 
Moayyedkazemi and Rahimirad 2018), Moreover, high CRP level was reported 
to be an independent risk factor for overall mortality (Xiong et al. 2017). 
Metanalysis performed by Gan et al in 2004 identified increase serum levels 
of  fibrinogen and TNFα in stable COPD patients, thus suggesting the presence 
of chronic systemic inflammation (W. Q. Gan 2004). 
Agusti et al have also shown a significant increase of IL-6, IL-8, fibrinogen, 
and TNFα plasma levels in COPD in comparison to both smoking and non-
smoking controls on the ECLIPSE cohort of about 1800 COPD patients and 
about 500 controls (A. Agustí et al. 2012). 
Cellular	component	of	systemic	inflammation	
Several research groups focused their attention on peripheral blood 
leukocytes to assess the changes occurring in these cells in COPD and their 
relation to the inflammatory pattern in the lungs. However, the data about 
peripheral leukocyte composition and functional changes in COPD are quite 
controversial.  
The first reported change in circulating leukocytes was an increase of 
neutrophil-to-lymphocyte ratio (NLR) in COPD, which was shown to correlate 
with mortality (Duffy et al. 2006; Pascual-González et al. 2018). Subsequently, 
the increase in NLR in stable COPD was confirmed by others and in some studies 
an inverse correlation between NLR and FEV1% in COPD patients was also 
demonstrated (Pascual-González et al. 2018; Furutate et al. 2016; İn et al. 2016). 
Several authors also reported NLR as a marker of COPD exacerbation, on-going 
or past (Lee et al. 2016; Taylan et al. 2017; Pascual-González et al. 2018). 
However, NLR elevation is not a feature specific to COPD, since an increased 
NLR value was also demonstrated in several other pathologies, such as 
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bacterial infection, breast cancer, type-2 diabetes, systemic lupus 
erythematosus, myocardial infarction and rheumatoid arthritis (Li et al. 2015). 
For instance, the increase of NLR during bacterial infection may explain the 
predictive capacity of NLR for COPD exacerbations.  
COPD related changes in total leukocyte count, as well as count and rate of 
main leukocyte populations available by the routine blood test were described 
in several studies. However, there is no consensus in the literature concerning 
these populations. Most authors report an increase of neutrophil count in stable 
COPD (Bilir et al. 2016; İn et al. 2016; Koch et al. 2007), while some report no 
significant difference (Taylan et al. 2017). Similarly, lymphocyte count decrease 
is reported in several papers (Bilir et al. 2016; İn et al. 2016; Taylan et al. 2017), 
while some authors report no difference (Koch et al. 2007). The same 
discrepancy persists for total leukocyte count, which is reported to be elevated 
in about 50% of papers analyzed (Fratta Pasini et al. 2016; Bilir et al. 2016; Koo 
et al. 2017; Taylan et al. 2017; A. Agustí et al. 2012) and not altered in another 
50% (İn et al. 2016; Stoll et al. 2015; Koch et al. 2007; Rumora et al. 2008; 
Scrimini et al. 2013). The possible reasons for such a discrepancy in the 
literature data are proposed in the discussion of this thesis.	
COPD was initially considered to be a neutrophilic disease. Indeed, 
neutrophil infiltrate is the main cellular component of BAL in COPD and it was 
shown to correlate with the severity of airflow obstruction (O’Donnell 2006). 
Also, matrix metalloproteinases and the main neutrophil cytokine IL-8 were 
detected at high levels in BAL of COPD patients (El-Shimy et al. 2014).  An 
increase of neutrophil count in peripheral blood of COPD patients was 
demonstrated in many studies. However, very few of them report significant 
correlations between circulating neutrophil count and disease parameters 
(Ellingsen et al. 2016) in contrast to NLR that was widely reported as an 
important severity and exacerbation risk marker (Pascual-González et al. 2018). 
20 
 
In addition to neutrophil count assessment, there are several publications 
describing alterations in neutrophil physiology in COPD, although these works 
are often not consistent. With respect to neutrophil chemotaxis, Yoshikawa et 
al reported impaired neutrophil chemotaxis in COPD (Yoshikawa et al. 2007), 
while Milara et al showed enhanced chemotactic activity of COPD neutrophils 
(Milara et al. 2012). Jaroenpool et al have shown a significant impairment of 
phagocytic ability of COPD neutrophils (mild-moderate cohort) in comparison 
to neutrophils of non-smoking and smoking controls. They have also 
demonstrated an increased ROS production by activated neutrophils of COPD 
patients and non-COPD heavy smokers in comparison to non-smoking controls  
(Jaroenpool et al. 2016). Oudijk et have shown an increased mRNA expression 
of IL-1β, IL-RA, MIP-1β, and CD83 in response to stimulation in neutrophils 
derived from severe and very severe COPD in comparison to the ones from 
moderate COPD or healthy controls. These expression levels correlated 
negatively with FEV1% in the COPD cohort (Oudijk et al. 2005).  
All main lymphocyte subpopulations, T, B, and NK cells, were demonstrated 
to be altered in circulation in COPD pathology. 
Despite known T cells involvement in COPD pathology and their increased 
number in the lungs of COPD patients, the data about circulating T cells are less 
certain. Chen et al demonstrated a disbalance in the CD8+ T population in COPD 
with a higher prevalence of IFNγ-producing Tc1 and lower prevalence of IL-4 
producing Tc2 (Chen et al. 2016), which goes in line with the general concept 
considering COPD as a Type-1 disease. Roberts et al have also shown 
differences in gene expression patterns between COPD- and control-derived 
circulating CD4+ T cells (Roberts et al. 2015). Additionally, they have reported 
a decrease of CD4+ T cells count in a moderate-severe cohort of COPD patients 
in comparison to non-COPD smoking-, sex-, and age-matched controls. 
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As well as for T cells, very few is known about circulating B cells changes in 
COPD, despite strong evidence of their involvement in COPD pathophysiology 
and demonstrated lung infiltration by B cells in COPD. Brandsma et al have 
shown a decrease of B cell percentage among lymphocytes of COPD patients in 
comparison to the control group, as well as a decrease of memory cell rate 
among the B cells in the COPD group, although this subtype was increased in 
smokers (Brandsma et al. 2009). Also, several papers reported an increased 
level of autoantibodies and B cell-activating factor (BAFF) in the blood of COPD 
patients (Núñez et al. 2011; Gao et al. 2020). The frequency of high-titer anti-
tissue autoantibodies was higher in the more severe COPD group (GOLD3-4) 
and the group with low gas transfusion capacity (DLCO%<50%). The level of 
BAFF, an essential factor for B cell survival, maturation, and differentiation, was 
increased in plasma of COPD patients in comparison to smoking or non-
smoking controls and it correlated with FEV1% in the COPD cohort. BAFF was 
also shown to inhibit apoptosis of CD8+ T cells and to induce IFNγ expression 
by CD4+ T cells and perforin and granzyme B expression by CD8+ T cells derived 
from peripheral blood of COPD patients (Gao et al. 2020).  
The rate of NK and NKT cells among CD3+ cells was shown to be increased in 
BAL fluid of COPD patients in comparison to either smoking or non-smoking 
controls. The increase in the NKT rate was mostly due to CD8+ NKT 
(Eriksson Ström et al. 2018). 
Data about circulating CD56+CD3+ NKT cells in COPD are controversial. Tang 
et al reported an increase of NKT count in COPD patients in comparison to healthy 
non-smokers (Tang et al. 2013), while Urbanowicz et al reported a decrease of 
NKT percentage in PBMC (Urbanowicz et al. 2009). Invariant NKT (iNKT) cell 
percentage of total leukocytes was also reported to be decreased in COPD together 
with mucosal-associated invariant T (MAIT) cells (Szabó et al. 2017). 
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Dendritic cells are found in COPD-associated lung lymphoid follicles together 
with T and B cells (Brusselle et al. 2009). However, circulating DC alterations in 
COPD are poorly described. Stoll et al have reported no difference in DC 
composition and pDC and cDC absolute count between COPD severe patients 
and current smokers. However, they have shown differences in surface 
molecules expression by  DCs, particularly an increased rate of OX40L+ cells 
among cDC and decreased rate of PD-L1+ cells among pDC (Stoll et al. 2015). 
Kalathil et al also observed no difference in pDC absolute count and rate among 
DC between COPD and non-smoking healthy controls (Kalathil et al. 2014). 
Monocytes have a dual role in immune response, being key players in the 
development as well as in the resolution of inflammation. Monocytes migrating 
to the lungs of COPD patients increase lung tissue destruction via production of 
proinflammatory cytokines, MMPs, and ROS. At the systemic level circulating 
monocytes of COPD patients showed an activated phenotype, including  higher 
levels of CCR5 expression in resting conditions (Ravi et al. 2017) and increased 
secretion of MMP-9 upon LPS stimulation (Aldonyte et al. 2003), as compared 
to monocytes of healthy donors. Impaired chemotaxis  (Ravi et al. 2017) 
together with an activated profile in resting conditions may suggest  monocytes 
from COPD patients to be rather “senescent” than “activated”. The phenomenon 
of immunosenescense was defined as an age-associated decline of the immune 
system efficiency due to global changes in the immune system towards an 
increased rate of more mature, sometimes primed or activated, cells with low 
proliferation capacity, low plasticity and often lower functional efficiency.  
Myeloid-derived suppressor cells, or MDSC, were detected in COPD by 
several authors. However, most of them did not check the suppressive capacity 
of these cells. MDSC are a heterogeneous group of monocyte- and granulocyte-
derived mature and immature cells sharing one common feature: the ability to 
suppress T cell activation/proliferation. To the moment, there is no clear 
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marker to distinguish MDSC from their non-suppressive counterpart. For 
monocytes most papers report that HLA-DRlow/- CD14+ monocytes have a 
suppressive capacity (Bronte et al. 2016), while for neutrophils none of the 
indications proposed, such as low density or FATP2 expression, can be 
unequivocally considered as a marker of suppressive cells (Veglia et al. 2019; 
Scapini et al. 2016; Marini et al. 2017). Kalathil et al have shown an increased 
percentage of low-density neutrophils (CD14−HLA-DR−CD11b+CD33+ cells) in 
PBMC of COPD patients compared to controls (Kalathil et al. 2014) but did not 




COPD was traditionally considered as a male disease  (Watson et al. 2004), 
but rising evidence shows that it probably equally concerns male and female 
populations. Also, according to the data from American Lung Association,  the 
number of women dying of COPD in the United States surpasses the number of 
men starting from the year 2000, even though the age-adjusted death rate per 
100’000 is still higher in men (American Lung Association 2013). They also 
reported a high prevalence of chronic bronchitis in females in comparison to 
males (56.7 cases of 1000 for female vs 29.6 cases for male) with almost no 
difference in emphysema prevalence.  
COPD diagnostics is based on anamnesis, including smoking history, 
symptom assessment, and spirometry. Since COPD symptoms are common for 
several lung diseases, including asthma, the main diagnostic tool is a 
spirometry test. However, the belief that COPD is a male disease can lead to 
underdiagnosis of women to have COPD.  Thus, Whatson et al reported that 
generally women are prescribed to undergo the spirometry test 20% less often 




With the group of 3265 male and female COPD patients Watson et al. 
reported that women with COPD suffer from more severe dyspnea despite 
younger mean age and less pack-year smoking burden (Watson et al. 2004). 
Physicians have usually related it to the fact that the same pack-year smoking 
index would mean a higher tobacco products burden per kilogram of body 
mass, as women generally weigh less than men. However, Tam et al have 
recently shown that an increase of airway resistance, induced by a long-term 
cigarette smoke exposure, is attenuated in ovariectomized mice, thus pointing 
to the role of sex hormones in COPD development (Tam et al. 2016). 
Phenotype	differences	
In addition to the abovementioned higher prevalence of chronic bronchitis 
in COPD female patients than in male, women were described to have less 
severe emphysema, particularly in the periphery of the lung, and stronger 
airway wall thickness increase (Martinez et al. 2007). Concerning the dynamics 
of COPD development, smoking women have a faster FEV1% decline than 
smoking men (Wen Qi Gan et al. 2006), which probably contributes to a much 
higher prevalence of women (71%) among the early-onset COPD group 
(Silverman et al. 2000). Interestingly, several studies have demonstrated that 
female non-smokers are more likely to develop COPD than male, which is 
reflected in both higher prevalence of females in the COPD non-smoker group 
(>80%, (Birring et al. 2002) and a higher rate of diagnosed COPD in the non-
smoking female population than in male (>5% and <3% for white females and 
males, respectively (Fuller-Thomson, Chisholm, and Brennenstuhl 2016). 
The treatment effectiveness is also not equal in male and female COPD 
population. Thus, females with COPD demonstrated less benefit from inhaled 
corticosteroid treatment than males, as well as females with asthma in 
comparison to the male group. Similarly, it was reported that emphysematous 
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female COPD patients demonstrate poorer airway obstruction reversibility 
than male patients (Han et al. 2007). 
 
AIM	
A great deal of controversy on the composition of circulating leukocytes in 
COPD patients exists, and no consensus has been reached for any of the 
parameters analyzed. So far, studies aimed at characterizing circulating 
leukocyte composition and status in a gender-specific manner have not been 
undertaken, regardless the significant gender-related difference of several 
features of this pathology. The hypothesis is that such controversial results may 
be derived from the composition of the cohorts investigated.  The aim of this 
study was to identify the role of gender in circulating leukocyte composition 
and state in COPD patients.  
The main goals of the present project are the following:  
1. Thorough characterization of the total number, frequency, 
phenotypic and functional characteristics of circulating leukocyte in 
stable male and female COPD patients; 
2. Identification of potential correlations between defined leukocyte 
traits and clinical/diagnostic features; 
3. Transcriptomic analysis of circulating polymorphonuclear 







We conducted a case-control study in a cohort of COPD patients recruited at 
Verona University Hospital between 2017 and 2019, belonging to the 
Respiratory Medicine operating unit, and control cohort free of COPD recruited 
from the general population. Research protocol was approved by the Ethic 
Committee of the Azienda Ospedaliera Universitaria Integrata Verona (protocol 
n. 42052/2015), in agreement with the principles of the Declaration of 
Helsinki, and written informed consent was acquired from all the subjects 
before their enrollment. Personal data were anonymized and numeric ID was 
assigned to each participant and used instead of the name. 
The diagnosis of COPD was based on the presence of symptoms, such as 
chronic cough, dyspnea, sputum production, history of exposure to risk factors 
for the disease, and spirometry exam. FEV1/FVC < 0.70 was used to confirm the 
presence of persistent airflow limitation with accordance to Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) recommendations. 
We collected demographic data including age, sex, body mass index (BMI), 
working history, physiological anamnesis (in particular smoking habit), 
pathological anamnesis and medications taken by each person; we investigated 
clinical features of COPD of each patient (duration, dyspnea MRC score, 
presence of nocturnal dyspnea, purulence presence and quantification of the 
sputum,  number of exacerbations in the last 12 months); Lung function 
parameters were evaluated for COPD patients, such as FEV1 – forced expiratory 
volume in 1 second, FVC – forced vital capacity, FEV1/FVC ratio, TLC – total 
lung capacity, RV – residual volume, RV/TLC ratio, ERV – expiratory reserve 
volume, IC – inspiratory capacity, IC/TLC ratio, DLCO – diffusing lung capacity 
for carbon monoxide , KCO – diffusing coefficients corrected for alveolar 
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volume. All above mentioned parameters were obtained as absolute values and 
as percent of predicted values for the subject of the same age, sex and height.  
 
 
Exclusion criteria for COPD patients and control subjects:  
 younger than 55 years old 
 the presence of active tumor pathology or a history of cancer within the 
previous three years 
 the presence of any autoimmune disease 
 the presence of infectious and/or inflammatory diseases in the acute 
phase 
 the presence of any lung disease other than COPD (asthma, lung fibrosis 
or other) 
 the intake of immunosuppressive or corticosteroid drugs orally or 
systemically. 
Leukocyte	count	and	distribution	assessment	
A venous sampling was performed for each donor using K2EDTA vials. 
Leukocyte count was obtained from routine test of automated differential 
blood cell count analysis performed in operative unit of Laboratory of Clinical 
Chemistry, Hematology and Clinical Molecular Biology of Hospital Borgo Roma. 
Estimation of different leukocyte populations count from Fluorescense-
Activated Cell Sorting (FACS) analysis was performed by multiplying the 
population percentage of total leukocytes obtained by flow cytometry using 
specific cell surface markers by total leukocyte count obtained by routine blood 
test. Neutrophil-to-Lymphocyte ratio (NLR) was calculated by dividing 




Human peripheral blood samples were stained with various monoclonal 
antibodies (mAbs) to determine the frequency of leukocyte subsets in each 
individual subject using flow cytometry. Briefly, 50 µl of fresh whole blood was 
used for each staining experiment, and the samples were incubated with 
fluorochrome-conjugated antibodies for 15 min at room temperature in the 
dark. Erythrocytes were lysed by incubation with BD Pharm Lyse™ lysing 
Solution (BD Bioscience, San Diego, CA, USA) for 5 minutes followed by washing 
and resuspension in FACS buffer (PBS + 2% FBS + 2mM EDTA) and immediately 
analyzed on 8-color MACSQuant Analyzer 10 flow cytometer (Miltenyi Biotec, 
Auburn, CA, USA). Flow cytometric analysis was performed following published 
guidelines (Cossarizza et al. 2019). Data were analyzed using FlowJo software 
(FlowJo 10.6.2, Ashland). A list of all fluorochrome-conjugated antibodies used 
is reported in Table 2. 
Maturation and activation status of PMN was performed on PMN collected 












Table 2. List of all fluorochrome-conjugated antibodies used for cytometric 
analysis 
Marker Clone Flurochrome Company 
CCR6 REA190 APC Miltenyi 
CCR7 (CD197) REA546 VioBlue Miltenyi 
CD10 HI10a PE BioLegend 
CD11b ICRF44 PE PEcy7 BioLegend 
CD11c REA618 APC Miltenyi 
CD127 HIL-7R-M21 PEcy7 BD 
CD14 REA599 VioBlue Miltenyi 
CD141 AD5-14H12 APC Miltenyi 
CD16 3G8 PerCP-cy5.5 APC/Cy7 BioLegend 
CD161 REA631 PE-vio770 Miltenyi 
CD19 LT19 PE-vio770 Miltenyi 
CD1c AD5-8E7 PE Miltenyi 
CD25 BC96 APC-cy7 BioLegend 
CD3 BW264/56 PerCP-Vio700 PE-vio770 Miltenyi 
CD35 E11 Vio-blue Miltenyi 




CD45 HI30 BV510 BD 
CD45RA T6D11 FITC Miltenyi 
CD45RO UCHL1 PerCP-Vio700 Miltenyi 
CD56 MEM-188 FITC BioLegend 
CD62L 145/15 APC Miltenyi 
CD66b G10F5 FITC BioLegend 
CD8 REA734 FITC APC-vio770 Miltenyi 
CRTH2 BM-16 PE Miltenyi 
CXCR3 REA232 VioBright FITC Miltenyi 
HLA-DR REA805 VioBlue Miltenyi 
HLA-DR L243 APC/Cy7 BioLegend 
MDC8 DD-1 FITC Miltenyi 
PD1 REA1165 APC Miltenyi 







Separation of peripheral blood mononuclear cells (PBMC) and 
polymorphonuclear cells (PMN) out of whole blood was performed by density 
gradient centrifugation of blood diluted 1:1 in pyrogen-free PBS over 
Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 
Purification of PMN, collected from the bottom of the tubes, from RBC 
contamination was performed by RBC sedimentation in 4% dextran solution in 
PBS followed by 50 seconds mixing in hypotonic solution (0.2% NaCl) RBC lysis. 
After RBC lysis PMN were washed with PBS. 
PMN	purification	on	magnetic	beads	
PMN purification for suppressive capacity test and RNA sequencing was 
performed by magnetic separation based CD66b-dependent positive selection 
using Miltenyi magnetic separation Kit (Miltenyi Biotec, Auburn, CA, USA). 
PMN, collected from Ficoll gradient separation as described in corresponding 
paragraph, were incubated with FITC-conjugated anti-CD66b antibody for 15 
min at room temperature. Then cells were washed with FACS buffer and 
incubated with anti-FITC magnetic beads for another 15 min at room 
temperature. After this, cells were washed again with FACS buffer and applied 
on magnetic columns, washed and eluted by FACS buffer according to 
manufacturer instructions. The final purity of granulocytes was >99.9%, as 
assessed by flow cytometry. 
T	cell	proliferation	analysis	
For proliferation analysis T cells were isolated from the whole blood of COPD 
patients and control donors using Pan-T Isolation Kit (Miltenyi Biotec, Auburn, CA, 
USA). Then BrDU incorporation-based test was performed with BrDU Kit (Roche 
Diagnostics GmbH, Mannheim, Germany) according to manufacturer’s 
instructions. Briefly, 40 000 cells/well T cells were plated in the wells of 96-well 
plate precoated with anti-CD3 antibody (Clone UCHT1, Biolegend, San Diego, CA, 
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USA) for three hours at 37 C. 200 000 cells/well PMN or the same volume of full 
RPMI were added to the T cells. Then anti-CD28 antibody (Clone CD28.8, 
Biolegend, San Diego, CA, USA) and full RPMI to the total volume of 200 µl were 
added. Cells were cultured for 72 hours. After 72 hours of co-incubation, BrDU for 
total concentration of 10M was added in all wells and the cells were incubated at 
37C for another 18 hours to allow dividing cells to incorporate BrDU. After 18 
hours cells were dried and stained with anti-BrDU antibodies and optical density 
was measured using VICTOR Multilabel Plate Reader (PerkinElmer Life Sciences, 
Boston, MA, USA). All samples were plated in triplicates. 
Induced	superoxide	anion	(O2·−)	production	
Superoxide anion production by neutrophils was assessed by Cytochrome C 
reduction test. This method of reactive oxygen species calculation is based on 
ferricytochrome C reduction to ferrocytochrome C by receiving an electron 
from O2·−, which leads to its spectrophotometric absorbance alteration. To 
perform the test, PMN were resuspended in HBSS (pH 7.4) containing 80 mM 
ferricytochrome C type III (MilliporeSigma, St. Louis, Missouri, United States) 
to 2×106 cells/mL and 20 ng/mL of PMA (MilliporeSigma, St. Louis, Missouri, 
United States) or 1 nM of fMLP (MilliporeSigma, St. Louis, Missouri, United 
States) was added to induce ROS production. Cytochrome C reduction was 
evaluated at 550 nm from the moment of stimulation and every 10 minutes to 
the total evaluation time of 2 hours. 
Reagents	and	cell	culture	
RPMI 1640 medium (Corning, NY, USA) containing 10% FBS (≤10 EU/mL 
endotoxin, MilliporeSigma, St. Louis, Missouri, United States) was used for cell 
culture. Cultures were maintained in a 37°C incubator containing 5% CO2.  
PBS solution was prepared by dissolving 10x DPBS (Corning, NY, USA) in 
sterile pyrogen-free water (B. Braun, Melsungen, Germany) 




Total RNA was extracted from resting granulocyte samples purified from 
whole blood of male COPD and age and matched healthy controls included in 
the “discovery cohort” (3 COPD patients and 4 controls) and “validation cohort" 
(26 controls and 24 COPD patients) using RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Demographic and 
clinical data for discovery and validation cohorts are represented in 
supplementary tables Table 11 and Table 12, respectively. For the “discovery 
cohort” PMN were purified by positive magnetic selection as described in the 
dedicated paragraph above (PMN purity >99.9%), while for “validation cohort" 
PMN purified from peripheral blood by Ficoll separation were used (PMN 
purity 99.6% [99.3 – 99.8]).  An on-column DNase digestion with the RNase-
free DNase I set (Qiagen), was performed to remove any contaminating DNA.  
RNA quantification was performed using the Nanodrop 2000 
spectrophotometer (Thermo Scientific, Massachusetts, USA).  
Transcriptomic	analysis	of	the	“discovery	cohort”	
RNA purified from granulocytes of donors enrolled in the “discovery cohort” 
was used to set cDNA libraries according to SmartSeq2 protocol (Picelli et al. 
2014). The choice of SmartSeq2 method, which allows sequencing from as little 
as 500pg of RNA, was dictated by the fact of low RNA yield from granulocytes. 
RNA-seq libraries were than sequenced on Illumina Next Seq500 (Illumina, San 
Diego, California, USA). 
Trimming for raw reads was performed with TrimGalore. a minimum of 15 
million fragments per sample were analyzed. After quality filtering according 
to the Illumina pipeline, reads were aligned to the GrCh38.p12 reference 
human genome (Genome Reference consortium) and the H.	 sapiens	
transcriptome (Ensembl, version 94) using HISAT2 aligner (Kim et al. 2019). 
Summed exon reads count per gene were estimated using HTSeq-count 
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(Anders, Pyl, and Huber 2014) with an intersection-nonempty mode for 
overlapping exons alignments and gene ID as feature ID. Differential gene 
expression analysis was performed with DESeq2 using the Wald test for two 
groups comparison and Likelihood ratio test (LRT) for multiple groups 
comparison. Genes considered as differentially expressed based on adjusted p 
value padj<0.05. Normalized gene expression levels were expressed as 
fragments per kilobase of exon for million reads mapped (FPKM). 
Transcriptomic	analysis	of	the	“validation	cohort”	
To validate the data of COPD signature obtained on the “discovery cohort”, 
3’Seq sequencing was performed on PMN samples from 24 male COPD patients 
and 26 male controls.  
RNA-seq library preparation was accomplished using the 3‘ mRNA-Seq 
Library Prep Kit (Lexogen GmbH, Germany); unique molecular indices (UMI) 
were used during the library preparation. Sequencing was performed on 
Illumina Next Seq500 (Illumina, San Diego, California, USA). 
Trimming for raw reads was performed with bbduk. After quality filtering 
according to the Illumina pipeline, reads were aligned to the GrCh38.p12 
reference human genome (Genome Reference consortium) and the H.	sapiens	
transcriptome (Ensembl, version 94) using STAR aligner according to 
manufacturer recommendations. UMI-based deduplication was performed 
using UMI tools. Summed exon reads count per gene were estimated using 
HTSeq-count (Anders, Pyl, and Huber 2014) with an intersection-nonempty 
mode for overlapping exons alignments. 
Differential gene expression analysis was performed using the negative 
binomial distribution-based method implemented in DESeq2 on the summed 
exon reads count per gene (Love, Huber, and Anders 2014). Gene expression 
normalization for sequencing depth was performed by internal 




Gene Ontology enrichment analysis was performed using Panther tools with 
GO database of the Gene Ontology Consortium as reference database. GO terms 
were considered enriched with padj <0.05. Semantic similarity of GO terms with 
Revigo tools was used to remove the redundant GO terms and visualize the 
summarized GO enrichment (Supek et al. 2011).  
Statistics	
All continuous variables are expressed as median [Q1-Q3] for all types of 
data distribution unless otherwise specified. The Shapiro-Wilk test was 
performed to control the distribution type. The Fisher’s exact test was used to 
compare proportions in different groups. Student T-test or Mann-Whitney 
U-test for normally and not-normally distributed data, respectively, were 
performed to compare the two independent groups. Analysis of variance 
(ANOVA) was used to compare more than two groups for normally distributed 
variables; Tukey post-test was used to identify significantly different groups. 
Where needed (as for ANOVA test), non-normally distributed variables were 
logarithmically transformed to normalize the distribution. The correlation 
coefficients and significance of correlations were analyzed using the Spearman 
Rank test. On correlation plots, linear regression lines with 95% CI are plotted 
to indicate the trend of the correlation. Linear regression analysis was also 
performed to assess more complex associations. All p-values were two sided. 
P < 0.05 was considered as significant. Wolfram Mathematica 12.0.0.0 software 





Demographic data for recruited COPD patients and age-matched controls are 
presented in Table 3. 
Table 3. Demographic data for recruited COPD and control subjects 
 Control COPD P	Value 
N 63 50  
Age 76.5 [66.3-80] 76 [70-80] 0.8 $ 
Sex	(Male/Female) 35/28 31/19 0.5 χ 
Smoking	
(never/ex/current/NA) 42/18/3/0 5/31/12/2 1 × 10
-4 χ 
Smoking	 pack‐year	
index	 0 [0-12] 30 [20-49.6] 6.3 × 10
-11 $ 
FEV1/FVC 0.77 [0.74-0.79] 0.50 [0.39-0.58] 3.3 × 10-21 t  
FEV1% 115 [103-127.5] 66 [47.5-79.5] 2.4 × 10-20 t 
BMI 26.7[24.2-29.4] 26.5 [24-31.5] 0.8 t 
Charlson	 index	 (except	
COPD)	 2 [0-2.25] 2 [1-3] 0.4
 $  
Hypertension	
(present/not)	 34/25 38/10 0.023
 χ 
Diabetes	(present/not) 10/53 7/43 1.0 χ 
CVD	(present/not) 11/45 14/36 0.4 χ 
Dyslepidemia	
(present/not) 16/40 17/29 0.4
 χ 
Arthrosis	(present/not)	 17/44 13/33 1.0 χ 
Hypothyroidism	
(present/not)	 7/53 4/42 0.8
 χ 





Leukocyte counts and neutrophil-to-lymphocyte ratio (NLR) are well 
recognized inflammatory markers associated with COPD. A recent 
comprehensive systematic review shows that the NLR value is higher in stable 
COPD patients than in healthy controls (Pascual-González et al. 2018). 
In order to provide a direct evaluation of leukocytes homeostasis, we 
studied the frequency and immunological characteristics of peripheral blood 
leukocytes derived from COPD patients. Total white blood cell (WBC) 
absolute numbers were comparable between the cohorts of COPD patients 
(6.5 [5.5–7.4] × 106 cells/mL) and control subjects (6.1 [5.3–6.9] 
× 106 cells/mL) (Figure 3 A). However, when the same analysis was performed 
stratifying subjects by gender, male COPD patients were characterized by a 
significant increase (6.9 [5.8–7.6] × 106 cells/mL vs 5.9 [5.3–6.6] × 106 cells/mL, 
p = 0.002), whereas female COPD showed a significant decrease (5.6 [4.2–6.8] 
× 106 cells/mL vs 6.3 [5.3–7.9] × 106 cells/mL, p = 0.038) in total leukocyte 
absolute numbers as compared to age and sex-matched controls (Figure 3 C). 
Additionally, the neutrophil-to-lymphocyte ratio (NLR) was assessed (Figure 3 B).  
NLR was higher in the COPD group compared to control, although the 
difference did not reach significance (2.4 [1.7–3.6] vs 2.1 [1.7–2.7], p = 0.070). 
As it is shown in Figure 3 D, no difference in NLR value between COPD and 
controls could be detected in the female cohort. Only the male COPD cohort 
showed a significant increase in NLR value as compared to controls        
(2.7 [2.0–4.1] vs 2.2 [1.7–2.7], p = 0.024) (Figure 3), indicating that the 
increased NLR value detected in the total COPD group versus the control cohort 








Figure 3. White blood cells count (A, C) and neutrophil-to-lymphocyte 
ratio (B, D) value in gender-mixed (A-B) and gender-stratified (C-D) COPD and 
control groups; light dots correspond to control group values and dark dots – 
to COPD. # – p = 0.07, * – p < 0.05, ** – p < 0.01. 
 
Leukocyte	composition	of	males	and	females	with	and	without	COPD	
An analysis of the absolute count (Figure 4 A) and of the frequency of 
leukocyte populations (Figure 4 B) showed that the increased WBC and NLR in 
the male COPD cohort as compared to sex-matched controls (Figure 3 C-D) can 
be attributed to the increase in the number of neutrophils 
(4.48 [3.30-5.04] × 106 cells/mL vs 3.47 [2.88-3.87] × 106 cells/mL, p = 0.002). 
Neutrophil frequency was significantly increased (Mean±SD value 64.0±8.3% 
vs 59.7±6.5%, p = 0.03) and lymphocyte frequency – significantly decreased 
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(Mean±SD value 24.3±7.3% vs 28.0±5.7%, p = 0.03) in male COPD group, while 
lymphocyte count was similar in COPD and controls. Absolute counts and 
frequencies of other general leukocyte populations were equally represented 
in male COPD and control groups (Figure 4  A and B respectively). On the 
opposite, the reduction of WBC in female COPD versus the respective control 
(Figure 3 C) results from a consistent reduction of each leukocyte population 
analyzed, even though significance was reached only for lymphocyte and 
monocyte populations (Figure 4 A). The leukocyte frequencies in female COPD 
were, therefore, indistinguishable from that of controls (Figure 4 B).  The exact 
values of main leukocyte populations count and rate for male and female 
cohorts are reported in supplementary tables Table 9 and Table 10, respectively. 
Collectively, the data show that gender is a relevant factor conditioning 
circulating leukocyte homeostasis in COPD and that a general leukopenia 
characterizes COPD in the female population. 
In order to better characterize all the leukocyte subsets, we performed a flow 
cytometry analysis of circulating leukocytes. Lymphoid and myeloid 
subpopulations were identified according to the gating strategy shown in 







Figure 4. Leukocyte composition in COPD and control males and females  
A – absolute concentrations of main leukocyte populations, B – main leukocyte 
populations frequencies of total WBC (sectors represent the mean percentage 






Figure 5. Gating strategy for lymphocyte subtypes 
Singlets were gated based on FSC-A and FSC-H parameters. Circulating 
leukocytes were defined as CD45+ cells. From them, after an exclusion of 
neutrophils by high granularity and lower CD45 expression and an exclusion of 
CD14+ monocytes (to reduce the noise in target populations identification), T 
cells (1) were defined as CD3+ cells. Among the T cells CD8+ CTL (2), CD4+ T 
helpers (3), and CD56+ NKT cells (4) were identified. NK cells (5) were 





Figure 6. Gating strategy for myeloid subtypes. Singlets were gated based on 
FSC-A and FSC-H parameters 
Circulating leukocytes were defined as CD45+ cells. From them, after an exclusion 
of neutrophils by high granularity and lower CD45 expression and an exclusion of 
T, B, and NK cells by their lineage markers (CD3, CD19, and CD56, respectively), 
Non-classical CD14-/lowCD16+ monocytes (1), intermediate CD14+CD16+ 
monocytes (2) and classical CD14+CD16– monocytes (3) were defined. Total 
monocytes were stained for HLA-DR expression and monocytic MDSC population 
(5) was defined as HLA-DR–/low. From CD14–CD16– cells pDC (6) were defined as 




Analysis of the three monocyte subtypes (classical, intermediate and non-
classical) showed no significant difference in monocyte composition in either 
male or female cohorts (Figure 7 A).  
CD14+HLA-DR– monocytic MDSC were also similar in number and 
percentage of total monocytes in COPD and control groups in both males and 
females (Figure 7 B). 
 
 
Figure 7. Monocyte subpopulations in COPD and control groups in male and 
female cohorts  
A – relative concentration of main monocyte subpopulations in total 
monocytes; B – CD14+HLA-DRlow/– monocytic MDSC count and rate of total 
monocytes; Class – classical CD14++CD16– monocytes, Inter – intermediate 
CD14++CD16+ monocytes, Non-class – non-classical CD14low/–CD16+ monocytes. 
 
Finally, with respect to dendritic cells, no differences in DC count between 
male/female COPD and control groups were observed (Figure 8 A). However, 
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while DC subtypes were equally represented in male COPD, a disbalance in 
conventional DC composition was observed in female COPD in comparison to 
control group (Figure 8 B). DC1 rate was increased while DC2 rate was 
decreased in female COPD vs controls, although none of these changes was 
statistically significant. 
 
Figure 8. Total count and composition of dendritic cells in COPD and control 
groups in male and female cohorts 
A – DC absolute concentration in whole blood; B – DC composition, represented 
as the rate of each subset in total DC; # – p<0.07. 
 
Characterization	of	the	circulating	lymphoid	cell	subtypes	in	COPD		
For the male cohort, where no difference in lymphocyte count was observed 
between COPD and controls (Figure 4 A), no changes were detected for 
lymphocyte subpopulations as well (Figure 9 A). In females the decrease of total 
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lymphocyte count was reflected in all lymphocyte populations, reaching 
significance, though, only for the B cells (Figure 9 A). This observation further 
strengthens the evidence that nearly all myeloid and lymphoid populations are 
involved in general leukocyte count reduction in female COPD. T cell 
subpopulations counts, namely CTL, T helpers, and NKT cells, were not 
significantly different between COPD and control groups for both male and 
female cohorts, although T helpers and NKT in females demonstrated the same 
trend of decreasing in COPD as other lymphocyte populations (Figure 9 B). 
 
 
Figure 9. Lymphocyte subpopulations (A) and T cell subpopulations (B) 
concentrations; * – p<0.05. 
 
T cell subsets analysis performed according to the gating strategy, depicted 
in Figure 10, revealed a significant increase of Treg cells frequency in T helpers 
in the COPD group in both male and female cohorts in comparison to respective 
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controls with no difference in other T helper subsets frequencies (Figure 11 A). 
Interestingly, Treg absolute count did not differ between COPD patients and 
controls. However, an increase of 40-70% in the percentage indicates an 
imbalanced T cell composition in the COPD group. Additionally, an imbalance 
in memory cell distribution among CTL was observed in female COPD, with a 
decreased rate of conventional CD45RO+ central (TCM) and effector (TEM) 
memory cells and a higher prevalence of terminally differentiated CD45RA+ 
TEMRA cells (Figure 11 C). None of such changes were observed in the male 
group. No changes were observed for CD4+ memory cell frequency in ether 
group (Figure 11 B). 
A summary of the significant differences identified between COPD and 





Figure 10. Gating strategy for T cell subtypes 
Memory T cells were defined as: CD62L+CD45RA– for central memory (TCM), 
CD62L–CD45RA– for effector memory (TEM), CD62L–CD45RA+ for senescent 
effector memory RA+ (TEMRA) and CD62L+CD45RA+ for naïve T cells. Type-2 
committed CD4 and CD8 cells (Th2 and Tc2) were defined by an expression of 
prostaglandin D2 receptor CRTH2. Other T helper subsets were defined by 
CCR6 and CXCR3 expression with Th1 defined as CXCR3+CCR6– cells, Th17 
defined as CXCR3–CCR6+ and Th1/Th17 hybrid population defined as 
CXCR3+CCR6+. CXCR3–CCR6– population consisted prevalently of T naïve cells 







Figure 11. T helper subsets frequencies in CD4+ T cells (A) and memory cell 
subtypes frequencies in CD4+ (B) and CD8+ (C) T cells; # – p<0.1, * – p<0.05, 







Figure 12. All differences between COPD and control groups with p<0.05 in 
male and female cohorts 
The difference between the medians is reported in each box as percentage of 
control values (Δ =  
 – 
 100%). Boxes are left empty 
when difference between COPD and control group are not significant (p≥0.05). 
Color represents the direction and the magnitude of the difference with more 
intensive red for an increase in COPD and more intensive blue for a decrease 




Male and female COPD patients recruited in this study did not differ 
significantly by symptom severity or any of assessed spirometry parameters 
represented as a percentage of predicted values, with an exception of the higher 







Table 4. COPD severity indicators and smoking status of male and female COPD 
 
COPD Male COPD Female 
 
 n Median (Q1-Q3) n Median (Q1-Q3) P value 
FEV1 % 30 59 (43±82) 19 70 (50.25±76) 0.5 t 
GOLD 30 2 (1±3) 19 2 (2±2.75) 0.7 $ 
FVC % 30 94.5 (77±111) 19 114 (100.75±122.75) 0.03 t 
FEV1/FVC 30 0.5 (0.38±0.6) 19 0.5 (0.4±0.55) 0.8 t 
IC/TLC 25 0.37 (0.32±0.45) 17 0.35 (0.31±0.43) 0.92 t 
MMEF% 19 23 (13.5±29.25) 12 18 (13±24.5) 0.4 t 
Dyspnea grade 29 1 (1±3) 19 1 (1±2) 0.3 $ 
DLCO% 24 79 (57.5±95.5) 15 74 (59.25±88.25) 0.6 t 
KCO% 24 95 (67.5±110) 15 82 (69.5±87.25) 0.2 t 
Smoking 
(current/ex/no) 
29 6/22/1 19 5/10/4 
0.7 χ for current 
vs ex+no 
$ – Mann-Whitney test, χ – Fisher’s exact test, t – Student T-test 
 
Other than spirometry parameters, smoking is an important confounder for 
COPD studies. With respect to this point, male and female cohorts did not differ 
significantly in the frequency of ex- and current-smokers (Table 4). However, 
female COPD patients had significantly lower cigarette smoke burden, 





Figure 13. Smoking pack-year index in male and female COPD patients and 
controls; * – p<0.05, *** – p<0.001. 
 
On the basis of this observation, we performed a multivariate analysis of 
variance (ANOVA) to assess if the smoking index (pack-year) has an impact on 
the differences described above. The total cohort was grouped by pack-year 
index into 3 groups: very light smokers with pack/years ≤ 15, light smokers 
with pack/year >15 and < 30, and heavy smokers with pack/year ≥ 30. 
Frequencies of very light, light, and heavy smokers are reported in Table 5. 
Table 5. Frequencies of very light, light, and heavy smokers in COPD and 
control male and female subjects 
 
Very light 




(≥ 30 pack-years) 
COPD male 2 6 21 
COPD female 7 5 7 
Control male 28 6  1 
Control female 21 5 1 
 
In addition to the influence of smoking, it is known that some of the frequent 
COPD comorbidities may cause systemic changes, including peripheral blood 
leukocytes alterations (Pettersson et al. 2011). On these bases, comorbidities 
were included in the ANOVA test to assess the possible influence of these 
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pathological conditions on the parameters that were shown to be significantly 
different between COPD and control groups. Comorbidities included in this 
analysis were diabetes, dyslipidemia, arthrosis, hypertension, cardiovascular 
diseases (CVD) and hypothyroidism (Table 6 and Table 7 for males and females, 
respectively). Smoking burden did not alter any of the systemic markers found 
to be significantly different in the COPD versus control group in either cohort. 
Pathological conditions, such as diabetes, dyslipidemia, and CVD, did modify 
per se the concentration of some of the leukocyte subsets previously identified. 
Nevertheless, and most importantly, the presence of COPD was an independent 
factor responsible for the statistically significant variation of the blood cell 
parameters identified in male and female cohorts, also after an adjustment to 
smoking habit and comorbidity conditions in most cases.  
Particularly, in male cohort COPD impact on WBC, neutrophil, and monocyte 
count, as well as on NLR and on Treg rate in T helpers, was significant after the 
adjustment to any of the confounders analyzed. Significance of COPD impact on 
neutrophil and lymphocyte percentage of total leukocytes was lost after the 
adjustment for Charlson index, dyslipidemia or arthrosis. However, 
dyslipidemia and arthrosis did not impact neutrophil and lymphocyte 
percentage. The impact of COPD on cytotoxic lymphocyte (CTL) rate in T cells 
lost the significance after the adjustment for most of confounders, except 
diabetes and hypothyroidism, even though the p value in most cases was still 
less than 0.1. Interestingly, the Charlson index was an independent predictor of 
the difference in CTL rate in male group. 
In female cohort alterations in T cells subsets and DC1/DC2 ratio increase in 
COPD were still significant after the adjustment for any of the comorbidities 
analyzed. The impact of COPD on monocyte and total leukocyte count lost the 
significance after the adjustment for hypertension and CVD (with the p value 
still close to 0.05 from monocytes and p = 0.08 for WBC). Diabetes and Charlson 
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index impact were not assessed in female cohort due to no COPD subjects with 
diabetes and very few subjects with Charlson index higher than 2. The decrease 
of B cell count in female COPD group lost the significance after the adjustment 
for any of the confounders analyzed, suggesting that B cell decrease is rather a 






Table 6. The impact of COPD comorbidities on significant leukocyte alterations 
in males. 










COPD 		0.002t	 0.003 0.022	 0.0008 0.002 0.002 0.002 0.001 0.002 
Con-
founder - 0.95 0.5 0.013 0.21 0.60 0.7 0.9 0.5 
Inter-
action 




COPD 		0.02t	 0.02	 0.2 0.02	 0.2 0.14 0.04	 0.02	 0.02	
Con-
founder 
- 0.3 0.2 0.008	 0.7 0.5 0.02	 0.010	 0.06 
Inter-
action 




COPD 		0.007t	 0.02	 0.2 0.02	 0.13 0.14 0.07 0.02	 0.02	
Con-
founder - 0.6 0.03	 0.002	 0.6 0.3 0.03	 0.007	 0.02	
Inter-
action -	 0.002	 0.3 0.2 0.11 0.2 0.6 0.4 0.8 
NLR	
COPD 		0.02$	 0.018 0.07 0.004 0.028 0.026 0.014 0.007 0.006 
Con-
founder - 0.6 0.8 0.013 0.20 0.96 0.15 0.029 0.10 
Inter-
action -	 0.044	 0.9 0.3 0.061 0.08 0.3 0.5 0.8 
Neutro	
COPD 		0.002$	 0.002 0.016	 0.0003 0.003 0.002 0.001 0.0006 0.0009 
Con-
founder - 0.6 0.9 0.003 0.8 0.8 0.3 0.10 0.5 
Inter-
action 




COPD 		0.012$	 0.033 0.010	 0.029 0.015 0.008 0.017 0.018 0.026 
Con-
founder 
- 0.98 0.5 0.3 0.4 0.8 0.5 0.9 0.6 
Inter-
action 
- 0.2 0.4 0.9 0.2 0.005 0.13 0.2 0.045 
The table represents the P values of the impact of COPD presence, the 
confounder and their interaction on the selected parameters, assessed by 
ANOVA. P values indicated in the column “None” are the unadjusted p values of 
pairwise comparison of COPD and control groups (by Student or 
Mann-Whitney test). 
t  TTest 
$  Mann-Whitney test 
* Smoking burden parameter was introduced as belonging to very light 
smoking, light smoking or heavy smoking group; 
** Charlson index parameter was introduced as belonging to a low 




Table 7. The impact of COPD comorbidities on significant leukocyte alterations 
in females. 
	 	 None	 Smoking*	dyslipidemia	 arthrosis	 Hypertension	 CVD	 Hypothyroidism	
WBC	
COPD 0.038t	 0.053	 0.06 0.031	 0.08 0.08 0.030	
confounder - 0.7 0.4 0.12 0.4 0.2 0.054 
Interaction - 0.07 0.6 0.7 0.98 0.7 0.5 
Mono	
COPD 0.03$	 0.021	 0.042	 0.026	 0.05 0.056 0.026	
confounder - 0.07 0.013	 0.3 0.5 0.9 0.57 
Interaction - 0.5 0.6 0.9 0.7 0.9 0.8 
Lympho	
COPD 0.03t	 0.033	 0.039	 0.028	 0.041	 0.043	 0.03	
confounder - 0.2 0.4 0.5 0.3 0.9 0.4 
Interaction - 0.7 0.6 0.4 0.8 0.9 0.6 
B	cells	
COPD 0.03$	 0.10 0.16 0.07 0.08 0.08 0.08 
confounder - 0.6 0.4 0.06 0.4 0.9 0.12 




COPD 0.016$	 0.049	 0.023	 0.030	 0.043	 0.032	 0.042	
confounder - 0.4 0.2 0.13 0.9 0.6 0.9 




COPD 0.004t	 0.002	 0.0011	 0.0005	 0.0016	 0.0018	 0.0017	
confounder - 0.2 0.2 0.4 0.8 0.8 0.8 
Interaction - 0.6 0.6 0.10 0.4 0.8 0.2 
TCM	%	
of	CD8	T	
COPD 0.047$	 0.056 0.038	 0.042	 0.042	 0.012	 0.030	
confounder - 0.7 0.3 0.2 0.3 0.036	 0.13 
Interaction - 0.7 0.15 0.9 0.2 0.0004	 0.12 
TEM	%	
of	CD8	T		
COPD 0.009t	 0.008	 0.004	 0.007	 0.0098	 0.0086	 0.0087	
confounder - 0.6 0.09 0.7 0.9 0.4 0.2 
Interaction - 0.10 0.035	 0.06 0.2 0.13 0.9 
The table represents the P values of the impact of COPD presence, the 
confounder and their interaction on the selected parameters, assessed by 
ANOVA. P values indicated in the column “None” are the unadjusted p values of 
pairwise comparison of COPD and control groups (by Student or 
Mann-Whitney test). 
t  TTest 
$  Mann-Whitney test 
* Smoking burden parameter was introduced as belonging to very light 






To understand whether the changes in circulating leukocyte composition are 
associated with COPD disease severity, we searched for correlations between 
the absolute number and percentage of each cell type identified by 
flow-cytometry and different clinical indicators of COPD severity.  Specifically, 
FEV1 %, FEV1/FVC, MMEF %, IC/TLC, dyspnea grade, and GOLD stage were 
chosen as representative of COPD severity. FEV1 %, FEV1/FVC, MMEF % and 
IC/TLC decrease with COPD progression, whereas dyspnea grade and GOLD 
stage increase (Figure 14). Thus, a direct correlation of the count or frequency 
of a cell type with FEV1%, FEV1/FVC, IC/TLC, and/or MMEF %, as well as an 
inverse correlation with GOLD and/or dyspnea indicates a progressive 
decrease of the given cell type along with increased disease severity. On the 
contrary, an inverse correlation of number and/or frequency of a given cell type 
with FEV1 %, FEV1/FVC, IC/TLC, and/or MMEF %, as well as a direct 
correlation with GOLD and/or dyspnea marks a progressive increase of the 
indicated cell type with COPD severity. 
Spearman rank test revealed that a number of circulating leukocyte 
populations correlate with one or more parameters of COPD severity. Figure 15 
illustrates a comprehensive heat map of the complete results of the correlation 
analysis.   
 





Figure 15. The number of significant correlations of various leukocyte 
populations count and rate with COPD progression, calculated separately for 
men (♂) and women (♀). The numbers in the squares indicate the number of 
COPD progression indicators that correlate significantly with a given 
parameter (of 6 indicators analyzed: FEV1%, FEV1/FVC, MMEF%, IC/TLC, 
GOLD stage, dyspnea MRC score). The plus or minus sign represents an increase 
or a decrease of the parameter with COPD progression (which means either 
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a decrease of FEV1%, FEV1/FVC, MMEF%, and/or IC/TLC or an increase of 
GOLD stage and/or dyspnea MRC score). Empty squares correspond to no 
significant correlations. 
 
Total white blood cell count, which is significantly higher in male COPD group 
as compared to respective controls (Figure 3 C), progressively decreases 
alongside with the increase in COPD severity (Figure 15), since it directly 
correlates with FEV1/FVC in this group (Figure 16 A). This is likely a 
consequence of the decrease in total lymphocyte count observed at later stages 
of the disease.  Indeed, neutrophil absolute count, which is significantly 
increased in male COPD as compared to relative controls (Figure 12), does not 
correlate with any of the selected indicators of COPD severity. At the same time, 
lymphocyte count directly correlates with FEV1% and inversely correlates with 
dyspnea MRC score (Figure 16 B). Among lymphocytes, the highest number of 
correlations was observed for B cell count (Figure 16 C) and NKT cell count 
(Figure 16 D). Specifically, B cell count directly correlates with FEV1%, 
FEV1/FVC, IC/TLC and MMEF%, while it inversely correlates with GOLD stage 
and dyspnea MRC (Figure 16 C). Similarly, NKT cell count directly correlates 
with FEV1%, FEV1/FVC, IC/TLC and inversely correlates with GOLD stage 
(Figure 16 D). Among the T cells, total T cell count (Figure 16 E) and T helper 
(CD4+T) count (Figure 16 F) decreased along with COPD severity.  
With respect to the myeloid compartment, an imbalance in dendritic cell 
composition associated with the disease severity was observed in male COPD 
(Figure 17), with an increase of DC2 rate and respective decrease of pDC/DC2 
ratio during progression towards more severe stages of COPD. Contrary to DC2, 







Figure 16. Significant correlations of total WBC (A) and lymphocyte 




Figure 17. Significant correlations of DC2 rate in DC (A) and pDC/DC2 ratio (B) 
with the GOLD stage in male COPD group 
 
In the female cohort, none of the leukocyte populations identified as 
significantly decreased in COPD as compared to control subjects (Figure 12) 
correlated with any of the clinical parameters analyzed.  Nevertheless, 
correlation analysis showed a direct correlation of CD4/CD8 ratio with FEV1% 
and MMEF% (Figure 18 A). The progressive decrease in CD4/CD8 ratio along 
with the disease severity more likely results from a CD4 T cell count decrease 
(Figure 18 B) as CD8 T cell count does not correlate with COPD progression.  
In addition, we observed an increase in frequency of some CD4 subtypes 
along with disease severity rise. Specifically: frequency of Th1 in CD4 T cells 
inversely correlated with FEV1% and MMEF%, and concurrently directly 
correlated with GOLD stage (Figure 18 C); frequency of Th2 in CD4 T cells 
inversely correlated with IC/TLC (Figure 18 D); frequency of Treg in CD4 T cells 
inversely correlated with FEV1%, FEV1/FVC and MMEF%, while directly 
correlated with GOLD stage (Figure 18 E).   
The rate of naïve cells among CD4 T directly correlated with FEV1% (Figure 
19 A). Terminally differentiated CD4 TEMRA cells number and rate among CD4 
T cells correlated directly with FEV1/FVC ratio (Figure 19 B-C), also decreasing 
with the disease severity rise, whereas central memory CD8+ T increased with 
COPD progression (Figure 19 D). In case of CD4 TEMRA count and rate, a 
pronounced bimodal distribution is observed, even despite a quite few 
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samples, with a group of patients with relatively high FEV1/FVC and 
CD4 TEMRA rate higher than 6 % and a group of patients with low FEV1/FVC 
and CD4 TEMRA rate lower than 3 %. 
 
 
Figure 18. Significant correlations of T cell subpopulations with COPD severity 










Figure 19. Significant correlations of memory T cell subpopulations with COPD 
severity indicators in female COPD group 
In female COPD, several populations of the myeloid compartment increase 
with the disease severity (Figure 15). Indeed, absolute counts of eosinophils 
(Figure 20 A), classical monocytes (Figure 20 B), and basophils (Figure 20 C) 
increased with the disease severity. Within monocytes, frequencies of different 
subpopulations changed along with the disease severity progression: on one 
hand a reduction of the frequency of intermediate monocyte (Figure 20 D) and 
frequency and count of the immunosuppressive CD14+CD16–HLA-DR–/low 
M-MDSC were observed (Figure 20 E-F), while, on the other hand, a parallel 
increase in the frequency and number of conventional classical monocytes 
(CD14+CD16–HLA-DR+) was detected (Figure 20 G-H). Interestingly, both 
absolute count and frequency of M-MDSC correlated exclusively with the 
parameters related to dynamic lung volumes, in case of MDSC rate – with all the 
four dynamic lung volume parameters analyzed (FEV1%, FEV1/FVC, MMEF%, 
and GOLD; Figure 20 E-F). Additionally, the DC1 percentage among total dendritic 
cells correlated directly with COPD progression in female COPD (Figure 20 I). DC1 
percentage was also increased, even though not significantly (Mean±SD of 5.3±2.4 




Figure 20. Significant correlations of myeloid subpopulations with COPD 
severity indicators in female COPD group 
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Interestingly, some of the parameters that correlated to GOLD stage in female 
COPD cohort, such as classical monocyte, eosinophil and basophil count and 
DC1 rate among total DC, also strongly correlated with each other in this group. 
None of these correlations were observed in male COPD (Figure 21). 
 
Figure 21. Correlation between COPD GOLD stage, classical monocyte count, 
eosinophil count, basophil count and DC1 rate in DC in female and male COPD 
cohorts. Numbers in the wells correspond to Spearman rho value of significant 
correlations, while empty wells correspond to no significant correlation.  
 
T	cell	activation	and	exhaustion	
Reduction of T cell count, which we observe with COPD severity rise in some 
T cell subtypes in both males and females, was described in other inflammatory 
pathologies, and it has been proposed to be determined by apoptosis of 
exhausted cells (Tavakolpour et al. 2020). To assess the level of exhaustion of 
COPD T cells we examined PD1 expression on the total, CD4+, and CD8+ T cells. 
Cytofluorimetric analysis showed that total T lymphocytes, as well as CD4 T and 
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CD8 T populations exhibit higher frequency of PD1+ cells only in the female 




Figure 22. Percentage of PD1 expressing cells among total, CD4+, and CD8+ T 
cells in male and female COPD and control subjects 
 
Despite no significant difference in the number of PD1-expressing 
lymphocytes in the male COPD group as compared to male controls, the level of 
membrane PD1 expression on T cells increased with COPD severity in this 
group (Figure 23), directly correlating with the GOLD stage and inversely 
correlating with IC/TLC, FEV1/FVC (Figure 24 A). PD1 expression level on CD4+ 
and CD8+ T cells also increased in males with COPD severity rise, in case of CD4+ 
T cells correlating directly with the GOLD stage and inversely with FEV1/FVC 
ratio, and in case of CD8+ T cells – inversely correlating with IC/TLC and 
FEV1/FVC (Figure 24 B and C, respectively).  
In female COPD PD1 expression in T cells also correlated with COPD severity 
(Figure 23), as indicated by the significant negative correlations of PD1+ cell 
rate in total T cells and PD1 expression level on CD4+ T cells with FEV1% 





Figure 23. The number of significant correlations between PD1 expression on 
T cells and COPD severity indicators (decrease of FEV1%, FEV1/FVC, IC/TLC, 




Figure 24. Correlation plots for the significant correlations between PD1 
expression on T cells and COPD severity indicators in male COPD group. For 




Figure 25. Correlation plots for the significant correlations between PD1 
expression on T cells and COPD severity indicators in female COPD group. For 
clarity, PD1 expression level is represented in Log scale. 
 
PD1 expression on the T cells significantly inversely correlated with the 
T cell count, which points to the relationship between T cell exhaustion and 
their decline in number (Figure 26). The significant correlation was observed 
only on the mixed cohort, while in male and female COPD groups separately it 
did not reach significance, more likely due to an insufficient number of subjects. 
The rate of PD1+ cells among the T cells also directly correlated with Treg rate 
and count in the pooled COPD cohort (Figure 27 A and B, respectively), 
indicating that inhibitory cell rate increases together with T cell susceptibility 
to inhibitory signals. 
 
Figure 26. Correlation between PD1 expression on T cells and T cell 
concentration in the blood in total COPD group. For clarity, PD1 expression 




Figure 27. Correlations of frequency of PD1+ cells among T cells with Treg rate 




Figure 28. Correlation of PD1 expression on CD8+ T cells with CD8+ TEMRA cell 











In addition to PD1 expression, the expression of CXCR3 and CCR6 homing 
molecules was measured on the cell surface of CD4+ and CD8+ T cells. Both 
CXCR3 and CCR6 expression levels were decreased on T helper subpopulations 
of COPD patients in comparison to the ones of control; the significance, 
however, was reached only for the male population (Figure 29 A, C). CXCR3 on 
CD8 T cells was also decreased in male COPD compared to control (Figure 29 B). 
HLA-DR surface expression was higher on CD4+ T cells in female COPD, 
although the difference did not reach the statistical significance level 
(172.5 [154.6 – 282.0] vs 26.8 [0 – 115.3], p = 0.056). 
 
Figure 29. Homing (CXCR3 and CCR6) and activation (HLA-DR) molecules 
expression on surface of CD4+ (A, C) and CD8+ (B, D) T cells in male (A-B) and 





The neutrophil population was significantly increased in male COPD patients 
in comparison to the control group and did not differ in number in females. To 
assess the differences of male and female COPD neutrophils from respective 
controls we focused on phenotypical and functional characterization of 
peripheral blood neutrophils.  
To estimate the activation status of neutrophils we measured the surface 
expression of well-established neutrophil activation markers: L-selectin 
(CD62L), complement receptor 1 (CD35), Fc-gamma immunoglobulin receptor 
III (FcyRIII, or CD16), and CD11b and CD11c (αM and αX, respectively). The 
expression of activation markers was measured by flow cytometry on mature 
(CD10+) peripheral blood neutrophils, gated according to the strategy depicted 
in Figure 30. 
Activated neutrophils are known to shade CD62L (Ivetic, Hoskins Green, and 
Hart 2019) and to decrease also surface CD16 expression upon activation 
(Kuijpers et al. 1991), together with an increase of CD11b (Ivetic, Hoskins 
Green, and Hart 2019). CD35 is expressed on granule membranes and appears 
on the cell surface as a result of the membranes fusion upon degranulation (van 
Staveren et al. 2018). The percentage of CD10+ mature cells among the total 
neutrophils was even higher in COPD patients compared to controls, thus the 
neutrophil increase in male COPD in comparison to control is not due to 
immature neutrophils mobilization from the bone marrow (data not shown). 
As shown in Figure 31, the level of activation of circulating neutrophils of COPD 
patients was comparable to neutrophils derived from control donors with a 
slight increase of surface expression of CD11b in male COPD neutrophils 
(p=0.052) and significant increase of CD16 expression on female 





Figure 30. Gating strategy for mature neutrophils. CD66b+ neutrophils were 
gated from alive CD45+ high-density fraction leukocyte population by exclusion 













Figure 31. Surface expression of maturation and activation markers on 
neutrophils, derived from peripheral blood of COPD and control subjects 
A – Representative histograms for surface expression of the markers on 




B – Box Whisker charts for main activation and maturation markers surface 
expression represented as median fluorescence intensity and interquartile 





Functional characterization of the PMN included reactive oxygen species 
(ROS) production.  
ROS production in response to conventional neutrophil stimuli phorbol 
myristate acetate (PMA) and formyl-methionyl-leucyl phenylalanine (fMLP), as 
assessed by cytochrome C reduction test in five COPD patients and six controls, 
was similar in COPD- and control-derived PMN (Figure 32). 
 
 
Figure 32. ROS production by stimulated COPD and control neutrophils 
Plots represent Mean O2 production (mM) by 2×105 cells/mL neutrophils 
stimulated by 20 ng/mL PMA (A) or 1nM fMLP (B) at different time points after 
stimulation. SD are plotted as filled areas of respective colors. 
 
In addition to neutrophil activation identified as ROS production, neutrophil 
suppressive capacity was assessed. Neutrophils have been demonstrated to 
gain immunosuppressive functions under specific circumstances, such as 
cancer and severe acute inflammation, as they have been shown to be able to 
suppress activated T cell proliferation (Delano et al. 2007; Cuenca et al. 2011). 
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The suppressive capacity of neutrophils from COPD was assessed by BrDU 
incorporation-based test.    
Purified T cells were incubated alone or with purified granulocytes (in 1:5 
ratio) and the intensity of cell division was estimated by an amount of BrDU 
incorporated into DNA during cell divisions. 
BrDU incorporation-based test showed no difference in proliferation 
capacity of T cells incubated with PMN purified from COPD or control subjects 
(Figure 33).  
 
Figure 33. TCR stimulation induced T cell proliferation after 90h of incubation 
alone or with either control- or COPD-derived PMN. OD – optical density, which 
corresponds to an amount of BrDU incorporated by cells and bound to 
antibody. 
 
Collectively, we can conclude that neutrophils from COPD have a higher 
surface expression of CD10 and, in case of COPD females, CD16, than those from 
control, while the ability to produce ROS following activation was comparable. 





To thoroughly characterize PMN purified from COPD, we performed RNA 
sequencing of purified PMN of four male control subjects and three COPD 
patients.  
Differential gene expression analysis revealed 231 genes to be significantly 
differentially expressed in COPD vs control (Figure 34). Among these, 93 genes 
were upregulated and 138 downregulated in PMN from COPD as compared to 
PMN from control subjects. Gene ontology enrichment analysis of the 
differentially expressed genes revealed a high enrichment in processes related 
to activation/degranulation and GTPase activity (Figure 35). Different types of 
GTPases are known to play an important role in neutrophil function, 
participating in the pathways essential for migration and adhesion 
(McCormick, Chu, and Vermeren 2019). Thus, despite a similar level of 
activation markers expression and induced ROS production in vitro, PMN from 
COPD differ from PMN of control subjects in their gene expression pattern, 








Figure 34. Heat map of gene expression in not-activated peripheral blood 





Figure 35. REVIGO semantic plot for GO enrichment analysis of genes, 
differentially expressed in peripheral blood neutrophils of COPD patients in 
comparison to age-matched controls. Each ball corresponds to significantly 
enriched GO term, while the size of the balls reflects log10 P value of GO term 
enrichment. 
 
To estimate the extent of upregulation and downregulation signals in COPD, 
we calculated the expression score for the genes significantly upregulated and 
downregulated in COPD granulocytes as compared to controls. The score was 
calculated as follows: 
1. Standardized gene expression (SGE) was calculated for each of the 
differentially expressed genes (Brkic 2013, Brkic 2006, Klrou 2004), 
according to the formula  , where X is the expression level of the 
gene of interest, 𝑋  is the mean value of the same gene in the control 




2. The “positive” and “negative” scores were obtained by summing up SGE of 
all the genes identified as significantly upregulated or downregulated in 
COPD as compared to control, respectively. 
The scores obtained for each of the seven subjects sequenced are shown in 
Figure 36. As expected, in both cases there is a significant difference in the 
score between COPD and control group. However, the negative counterpart of 
the differentially expressed genes is more pronounced. 
 
Figure 36. Overall gene expression scores obtained for genes significantly 
downregulated (A) and upregulated (B) in COPD. Mean±SD and individual 
samples values are presented; * – p ≤ 0.05 , *** – p ≤ 0.001.  
 
Differentially expressed genes together with the scores identified in the 
discovery cohort, were subsequently validated in a second cohort (validation 
cohort) consisting in 24 COPD and 26 control subjects. PMN RNA from the 
validation cohort were sequenced and 87 of 93 genes upregulated in the 
discovery cohort and 100 of 138 genes downregulated in the discovery cohort 
were validated.  
Consistently with the discovery cohort, the “negative” COPD score was 
significantly lower in COPD patients than in controls (Figure 37 A) and 
“positive” COPD score – significantly higher (Figure 38 A). “Negative” score 
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alone distinguished COPD patients from age-matched control donors with the 
sensitivity of 70.8 % and specificity of 65.2 % for the cutoff of -27.5. Area under 
the Receiver Operating Characteristic (ROC) curve for the model, based only on 
downregulated genes score, reached 0.75 (Figure 37 B).   
 
 
Figure 37. “COPD score” value for downregulated genes in validation cohort of 
27 male controls and 26 male COPD patients  
A – COPD score values (Mean±SD and individual samples values are presented), 
B – ROC curve for COPD discrimination by the score values; ** – p<0.01. 
 
Same but with lesser extent was true for the “positive” COPD score – the area 
under the ROC curve for the classifier based on upregulated genes was 0.68, 





Figure 38. “COPD score” value for upregulated genes in validation cohort of 27 
male controls and 26 male COPD patients 
A – COPD score values (Mean±SD and individual samples values are presented), 
B – ROC curve for COPD discrimination by the score values; * – p<0.05. 
 
“Negative” COPD score significantly correlated with the age in COPD, but not 
in control group (Figure 39). After the adjustment for the age, “negative” score 
was found to be significantly associated with emphysema level in COPD group, 
as assessed either by gas transfusion capacity or by direct CT scans analysis 
(Table 8).  However, more patients with available CT scans are needed to 
validate this indication. 
 
Figure 39. Downregulated genes score correlation with the age in male control 







Table 8. The association of COPD score for downregulated genes with 
emphysema severity indicators adjusted for age 
 P	value R2adjusted	* n 
DLCO % adjusted for Age: 0.054 0.54 19 
KCO % adjusted for Age: 0.021 0.58 19 
Emphysema level adjusted for Age: 0.0056 0.96 7 
 * R2adjusted for the model including Age, emphysema indicator and their interaction 
 
Collectively, transcriptomic profile of the granulocytes from COPD patients 
revealed a COPD-specific signature, that distinguished these cells from the 
control counterpart, despite a comparable phenotypic and functional features. 
The pronouncement of the negative counterpart of this signature is likely to 






The main results of this work can be summarized as follows: 
1. Gender plays a central role in driving changes of the composition of 
circulating leukocyte in stable COPD subjects:  while neutrophilia and increased 
neutrophil to lymphocyte ratio are the hallmarks of COPD in male, female 
COPD, on the contrary, are characterized by a generalized leukopenia. 
2. A decrease of the absolute number of lymphoid population (B cells, 
T cells, NKT, CD4T cells and CD8 naïve T cells) in male, and an increase of the 
absolute number of myeloid population (eosinophils, basophils, classical 
monocytes) in female correlate with the degree of COPD severity.  
3. Reduction of different populations of T cells along with COPD severity 
was observed in both males and females. Such a decrease is likely due to T cell 
exhaustion, as suggested by increase in PD1+ cells.  
4. Neutrophils purified form male COPD patients do not display significant 
changes at the functional level (as assessed by induced ROS generation and 
activation state). Nevertheless, they are characterized by a distinct 
transcriptional profile. Analysis of COPD granulocyte transcriptome allowed us 







The number of accompanying comorbidities and the presence of systemic 
inflammation associated with symptoms worsening and comorbidities 
progression make COPD to be considered as a systemic disease.  Several 
research groups focused their attention on peripheral blood leukocytes 
composition and immune-phenotype to assess the changes occurring in these 
cells in COPD and their relation to the inflammatory pattern in the lungs. The 
overall picture derived from these studies is quite conflicting, and the results of 
these studies range from reporting a significant increase in total leukocyte 
count (Taylan et al. 2017; Koo et al. 2017; Bilir et al. 2016; A. Agustí et al. 2012; 
Fratta Pasini et al. 2016) and in neutrophil count (Bilir et al. 2016; İn et al. 
2016), to describing no difference of assessed leukocyte concentrations 
between the COPD and control groups (Sun et al. 2018; Koch et al. 2007; 
Scrimini et al. 2013). 
 Our data obtained on the male COPD cohort are consistent with most other 
reports: we observed an increase of WBC and neutrophil count, which also was 
the main driver for significant NLR increase in the male group. Surprisingly, 
these findings have not been confirmed in the female cohort. Conversely, we 
demonstrate for the first time that circulating leukocytes in female COPD are 
characterized by a significant leukopenia, resulting from a decrease of almost 
every leukocyte population. Other than highlighting that alteration of the 
immune system homeostasis in subjects with COPD occurs in a gender-specific 
manner, this finding helps to reconcile the conflictual data of the literature. In 
fact, one of the reasons for such discrepancy may be the heterogeneity of the 
composition of the COPD cohorts under investigation. Indeed, retrospectively 
we analyzed the gender composition of the cohorts recruited in these 
contradictory studies and found out that the studies reporting a significant 
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increase in WBC and neutrophil count have been performed on cohorts 
composed predominantly of male subjects, while no difference in circulating 
leukocyte parameters have been reported for studies performed on gender-
balanced cohorts.  
Remarkably, WBC count in female COPD was not increased as compared to 
their respective controls, but it even occurred to be significantly decreased. The 
reduction of leukocyte number was observed in all the main leukocyte types and 
reached significant values for monocytes, lymphocytes and B cells.  Decrease in 
WBC count can be consequent to different conditions. For instance, one of the 
most frequent conditions that can possibly lead to WBC count decrease is 
hypothyroidism. Hypothyroidism was previously reported to cause leukopenia, 
more likely through a general bone marrow depression (Kawa et al. 2010). 
ANOVA analysis of the female cohort recruited in this study, confirmed a 
significant reduction in WBC count in females affected by hypothyroidism, 
regardless the presence of COPD pathology. Nevertheless, we can exclude this 
pathological condition as the main driver of leukopenia in female COPD, since 
WBC counts remained significantly lower in female COPD vs control even after 
removing subjects affected by hypothyroidism (not shown).  
Lymphopenia occurs also in a number of conditions characterized by acute 
inflammation, such as respiratory viral infection and sepsis (Mazzoni et al. 
2020; Venet et al. 2010), and autoimmune diseases (Schulze-Koops 2004). 
Inflammation-related lymphopenia has been shown to result from three main 
mechanisms: (I) lymphocyte migration from circulation to inflamed tissue 
(Cavaillon and Adib-Conquy 2010); (II) bone marrow deprivation (Binder et al. 
1997); (III) lymphocyte exhaustion followed by their apoptosis through PD1-
PDL1, Fas-FasL, or other pathways (Tavakolpour et al. 2020; Aggarwal, 
Gollapudi, and Gupta 1999; Cavaillon and Adib-Conquy 2010). Lymphocyte 
apoptosis was associated with the elevated levels of IL-6 and TNFα. 
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TNFα-induced apoptosis was demonstrated for monocytes and T cells 
(Aggarwal, Gollapudi, and Gupta 1999; Shen et al. 2005). Both TNFα and IL-6 
plasma levels are known to be elevated in COPD patients (Yasuda et al. 1998; 
W. Q. Gan 2004), suggesting that an increased lymphocyte apoptosis may be 
responsible for a decline in lymphocyte number in COPD. PD1-PDL1 interaction 
is one of the main triggers of apoptosis of activated and exhausted T cells 
(Mandal, Mehta, and Prajapati 2018). Kalathil et al have previously shown an 
increase of PD1 expression on the surface of circulating CD4 T cells, as well as 
an increase in Treg percentage and count in COPD patients compared to healthy 
controls (Kalathil et al. 2014). Here we confirm an increased PD1 expression on 
circulating CD4 T cells and report the same for CD8 T cells (at least in female 
and severe male COPD). We also observed a significant correlation between 
PD1 expression on T cells and immunosuppressive Treg subset frequency and 
count. Remarkably, we showed that PD1 expression level on T cells significantly 
inversely correlated with T cell count, indicating that PD1-triggered T cell 
apoptosis is involved in COPD lymphopenia. 
CD4 T cell count decreased with COPD progression in both male and female 
cohorts, while CD8 T cell count was similar in COPD and control and did not 
correlate with COPD severity.  These results are consistent with the findings of 
Tang et al. and Roberts et al, who demonstrated a decrease of CD4 T cell count 
in moderate-to-severe COPD patients in comparison to gender-, age-, and 
smoking matched controls and no difference in CD8 T cells (Tang et al. 2013; 
Roberts et al. 2015). Possible pathological role of CD4 T cells in emphysema 
development was shown by Taraseviciene-Stewart et al, who demonstrated 
that adoptive transfer of syngeneic CD4+ lymphocytes that had been sensitized 
to endothelial cell antigens resulted in the development of emphysema in naïve 
rats (Taraseviciene-Stewart et al. 2005). Roberts et al. in their paper relate 
circulating CD4 T cell decrease to their possible migration to the inflamed lungs. 
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However, it does not explain an absence of changes in CD8 T cell count, as both 
CD4 and CD8 T cells infiltrate the lungs of COPD patients.  
We observed a significant increase of Treg percentage in CD4 T cells in 
both male and female COPD patients in comparison to respective controls. 
In the female COPD group, Treg increase correlated with most of the clinical 
parameters related to the disease progression, such as FEV1%, GOLD, 
FEV1/FVC, and MMEF%, while in males such correlations were not 
observed. There are controversial data about circulating Treg in COPD. 
Kalathil et al reported an increase of the percentage and absolute 
concentration of CD127–CD25+Foxp3+ Treg cells in COPD in comparison to 
control (Kalathil et al. 2014), while Hou et al reported a decrease in total count 
and percentage among CD4 T cells of two Treg subpopulations 
(CD25+++CD45RA+ and CD25+++CD45RA−) in COPD in comparison to healthy 
donors and an increase of a third and prevalent Treg subpopulation 
(CD25++CD45RA−) percentage and count (Hou et al. 2013). Such inconsistent 
data may reflect differences in Treg definition: we identified Treg as 
CD3+CD4+CD127–CD25+ cells,  without assessing Foxp3 intracellular 
expression,  according to Seddiki et al, who have shown a strong 
correspondence of this phenotype to Foxp3 expression (Seddiki et al. 2006). 
Nonetheless, correlation of this population with those described in other works 
needs to be investigated, and might explain the discrepancy of the results.  
We also observed a decrease of homing molecules CXCR3 and CCR6 
expression on the surface of T cells in the total and male, but not in the female 
cohort.  Chemokine receptor CXCR3 is known as a type-1 immune response 
molecule. It is expressed on Th1-committed CD4+ T cells and activated Th17 
cells acquiring Th1 functions – Th1/17 population (Cosmi et al. 2011), but also 
on other leukocytes. In CD8+ CTL, CXCR3 expression characterizes TEM and 
TEMRA memory cell subpopulations (Willinger et al. 2005).  In 2007 Koch et al. 
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reported an increase of CXCR3+ cells proportion in CD8 T cells in currently 
smoking COPD patients compared to smoking or non-smoking healthy donors 
(Koch et al. 2007). In our cohort, we observed a decrease of CXCR3 expression 
by CD8 T cells in COPD patients, which was significant for the total and male 
cohorts, but not significant in females. The discrepancy with the data reported 
by 2007 Koch et al. can be given by the difference in age, as their small cohort 
consisted of much younger subjects. We also demonstrated a significant 
decrease of CXCR3 expression on Th1 and Th1/17 cells of male but not female 
COPD patients, as well as CCR6 repression on Th17 and Th1/17 cells. The 
decrease of homing molecules expression may be either a response to anti-
inflammatory signals that decrease activation and/or migratory capacity of 
T cells or a result of the recent migration of competent cells to inflammatory 
sites so that the cells left in the circulation express lower levels of homing 
molecules. Interestingly, Th1/17 cells – activated Th17 cells that are able to 
produce both IFNγ and IL-17 and appear to be involved in different chronic 
inflammatory diseases (Cosmi et al. 2011), demonstrated a decrease of both 
CXCR3 and CCR6 surface expression.  Grumelli et al have previously shown an 
increased surface density of CXCR3 chemokine on lung T cells of 
emphysematous patients in comparison to controls (Grumelli et al. 2004). This 
favors the hypothesis of the excessive migration of CXCR3bright cells to the lungs 
rather than CXCR3 downregulation.  
In addition to CD4 T cells, we demonstrated a decrease of NKT count with 
COPD progression in the male cohort. To our knowledge, there are no 
publications assessing NKT count alterations in COPD. However, 
Urbanowitz et al have previously shown NKT percentage in PBMC to be 
decreased in moderate-severe COPD patients in comparison to smoking or non-
smoking controls (Urbanowicz et al. 2009). 
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The involvement of B cells in COPD pathology is actively studied. Several 
articles report an increase in B cell count in different lung areas in COPD. 
Moreover, B cell-enriched lymphoid follicles were found in the lungs of COPD 
patients. The number of these lymphoid follicles was associated with an 
emphysema-prevalent phenotype and with a poor prognosis of the disease 
(Polverino et al. 2016). However, very little is known about circulating B cells 
in COPD. Brandsma et al. have reported a decreased B cell percentage in COPD 
patients in comparison to either smoking or non-smoking healthy donors 
(Brandsma et al. 2009).  We demonstrated that B cell count was decreased in 
females with COPD independently of the GOLD stage, while in males there was 
no significant difference in B cell count between COPD and control group. 
However, B cell count in males correlated significantly with all the six COPD 
severity indicators analyzed, while none of such correlations were observed in 
females. This is explained by non-linear dynamics in B cell count change during 
COPD progression in the male group with a significant increase of B cells 
number at GOLD1-2 and a significant decrease at GOLD3-4 stages (data not 
shown). Why the dynamics of B cell count changes in COPD differs in males in 
females remains unclear. The explanation can be related to sexual dimorphism 
in gene expression signature of B cells, demonstrated by Fan et al on healthy 
males and females (Fan et al. 2014), which means that male and female B cells 
may respond differently to similar stimuli. 
Intriguingly, systemic changes occurring in females, but not males, with 
COPD progression resemble the immune signature of asthma. The increase of 
eosinophil, basophil, and classical monocyte count, which we observed in the 
COPD female cohort with the disease progression, was previously shown for 
asthma (Tomita et al. 1995; Hill et al. 2014), where peripheral blood classical 
monocytes expansion potentiated airway hyper-responsiveness (Kowal et al. 
2012). Hayashi et al also demonstrated a relation between Type-2 shift of 
immune response and an increase of DC1 (CD141+ DC) and a decrease of DC2 
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(CD1c+ DC) in atopic diseases (Hayashi et al. 2013). In the COPD female cohort, 
we also observe an increase of DC1 rate in the COPD group (p=0.055, data not 
shown) that correlates with the disease progression. Moreover, the 
abovementioned parameters correlate not only with COPD severity but also with 
each other, while none of these changes occur in male COPD, except the classical 
monocyte count increase, which, however, correlates neither with COPD 
progression (Figure 15) nor with eosinophil or basophil count (Figure 21). 
The relations between asthma and COPD and their association with gender 
are under active investigation. Several authors have reported that women not 
only develop asthma more frequently than men, but also more frequently 
demonstrate asthma-COPD overlap syndrome (Wheaton et al. 2016; de Marco 
et al. 2013).  Roberts et al. also reported that women with confirmed diagnosis 
of COPD had significantly higher frequency of allergy in their respiratory 
medical history, than men. In our cohort we also observed higher prevalence of 
allergy in COPD women than in men with no such difference in the control 
group (1 over 30 in men and 5 over 19 in women with COPD, p=0.027). 
 
One of the most unexpected results was a decrease of M-MDSC cell count and 
rate in severe female COPD in comparison to mild control groups. The role of 
MDSC decrease in COPD pathology is yet totally unknown. There are several 
papers describing MDSC in COPD. However, all of them describe different 
populations: low-density neutrophils (CD14−HLA-DR−CD11b+CD33+ cells in 
PBMC, (Kalathil et al. 2014)), immature monocyte precursors 
(Lin−CD14−HLA-DR−CD11b+CD33+, (Tan et al. 2014)) and mature HLA-DR−/low 
classical monocytes (CD14+HLA-DR−CD11b+CD33+, (Tan et al. 2014)). Tan et al 
reported no significant difference in in MDSC proportion among PBMC on a 
small cohort of COPD patients and smoking and of non-smoking controls 
(donor’s sex is not reported) (Tan et al. 2014). In the present work, we also did 
not observe significant difference in MDSC count or rate between COPD 
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patients and control group, even in female cohort, where MDSC count and rate 
correlated with COPD severity indicators. A possible explanation may be that, 
similarly to B cells in male cohort, MDSC change along with COPD severity in a 
non-linear manner. In fact, we observed that the rate of MDSC in the monocytes 
remained similar to control values up to GOLD2 and significantly decreased at 
GOLD3-4 COPD stages (data not shown). This hypothesis should be confirmed 
in a larger cohort. 
 
Neutrophils	phenotypical	and	transcriptomic	alterations	
An increase of neutrophil count in stable COPD, widely described in the 
literature, occurred to be a characteristic of only male population. This goes in 
line with the finding of Deitch et al. who have shown in rat model that 
testosterone may be responsible for stronger neutrophil activation during 
non-infectious inflammatory states in males than in females (Deitch et al. 2006). 
In the present work we have demonstrated a significant CD10 (neutral 
endopeptidase) surface expression increase in COPD patients in comparison to 
controls in both male and female cohorts, as well as CD11b increase on male 
COPD neutrophils and CD16 increase on female COPD neutrophils. Long-lasting 
phenotypical changes in resting circulating neutrophils were recently 
demonstrated in the paper of Moorlag et al. on healthy donors receiving BCG 
vaccination (Moorlag et al. 2020).  They demonstrated a shift of circulating 
neutrophils towards expressing higher CD10, CD11b, and CD16 and lower 
CD62L 3 months after the vaccination. They describe these changes to be most 
likely mediated by epigenetic modifications at the promoter sites of genes 
essential for antimicrobial function, as they also demonstrated increased levels 
of H3K4me3 upon BCG vaccination. The increased surface expression of CD11b 
that we observed on a trend level for male COPD group was also shown by 
Blidberg et al. on prevalently male COPD patients compared to sex-matched 
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controls, although CD11b increase in their study did not reach significance as 
well (Blidberg et al. 2012). Chronic inflammation-induced trained immunity in 
neutrophils may be a part of a pathological loop of well-established neutrophil-
related lung injury in COPD and may partially explain why smoking cessation 
in COPD patients often does not lead to the remission. 
Despite quite few phenotypical changes and no functional changes observed 
in neutrophils from COPD, the transcriptomic analysis of the discovery cohort 
revealed a set of 231 genes that differ significantly between COPD and control. 
This COPD-specific gene signature (reduced to 187 genes) was than validated 
on validation cohort of 50 donors, showing a significant difference in the 
cumulative gene scores between COPD and control granulocytes. In addition, 
after the adjustment for age, the cumulative score of the genes, identified in the 
discovery cohort as downregulated in COPD, was significantly associated with 
emphysema grade in COPD patients of validation cohort. However, more 
samples with available CT scans are needed to validate this indication and to 
assess the predictive capacity of this signature for emphysema grade.  
According to the results of gene enrichment analysis, the most affected 
biological processes in COPD PMN were neutrophil degranulation and GTPase 
activity. GTPases play an important role in neutrophil biology and are involved 
in a vast majority of neutrophil immune functions – migration, degranulation, 
phagocytosis, ROS production, and NET formation (McCormick, Chu, and 
Vermeren 2019; Tackenberg et al. 2020). GTPases are also involved in 
neutrophil apoptosis, which was shown to be significantly decreased in 
COPD-derived neutrophils in comparison to healthy controls (Zhang et al. 2012).  
Based on our findings, it can be concluded that, although the main COPD 
manifestations are related to the lungs, there are prominent changes in 
circulating leukocytes related to COPD development and its severity. These 
changes include alterations in cell count, cell composition disbalance, changes 
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in the level of surface expression of activation markers and homing molecules, 
and transcriptomic modifications. Interestingly, the changes occurring in male 
and female cohorts were not similar. For the future, it would be very interesting 
to investigate whether also granulocytes from female COPD are characterized 
by a transcriptomic signature and, in case, identify shared or distinct traits of 







Table 9. Main leukocyte populations count and rate of total WBC in male COPD 
and control groups 
Male cohort 
Median [Q1-Q3] population count, 106 
cells/mL 
Mean±SD population percentage 
in total WBC, % 
Control COPD P value Control COPD P value 
Neutrophil 3.47 [2.88-3.87] 4.48 [3.3-5.04] 0.0023 $ 59.71±6.49 64.01±8.25 0.025 t 
Lymphocyte 1.62 [1.35-1.87] 1.66 [1.12-1.86] 0.6 t 28.04±5.66 24.28±7.33 0.026 t 
Monocyte 0.48 [0.44-0.60] 0.56 [0.47-0.64] 0.2 t 8.71±1.92 8.52±2.18 0.5 $ 
Eosinophil 0.13 [0.08-0.20] 0.14 [0.07-0.21] 0.9 $ 2.81±2.05 2.56±1.67 0.6 $ 
Basophil 0.04 [0.03-0.06] 0.04 [0.03-0.05] 0.5 $ 0.73±0.25 0.63±0.35 0.07 $ 
$ – Mann-Whitney test, χ – Fisher’s exact test, t – Student T-test 
 
Table 10. Main leukocyte populations count and rate of total WBC in female COPD 
and control groups 
Female 
cohort 
Median [Q1-Q3] population count, 106 
cells/mL 
Mean±SD population percentage 
in total WBC, % 
Control COPD P value Control COPD P value 
Neutrophil 3.82 [3.14-5.01] 3.08 [2.40-4.49] 0.15 
t
 58.69±8.07 58.20±10.75 0.7 
$
 
Lymphocyte 1.99 [1.57-2.39] 1.55 [1.30-1.85] 0.029 
t
 29.35±6.10 30.63±10.48 0.6 
t
 
Monocyte 0.52 [0.40-0.68] 0.4 [0.35-0.51] 0.03 
$
 8.44±2.36 7.93±2.05 0.4 
$
 
Eosinophil 0.15 [0.10-0.25] 0.12 [0.08-0.18] 0.3 
$
 2.86±2.25 2.52±1.05 0.8 
$
 
Basophil 0.04 [0.02-0.06] 0.04 [0.03-0.05] 0.6 
t
 0.66±0.35 0.72±0.33 0.6 
t
 








Table 11. Demographic and clinical data of the “discovery cohort” participants 
 COPD 1 COPD 2 COPD 3 Control 1 Control 2 Control 3 Control 4 
Age 73 74 83 74 93 94 81 
Smoking  EX EX EX EX NEVER NEVER NEVER 
Smoking  
pack-year index 
2.9 30 43.8 150 0 0 0 
FEV1% 43 82 32 115 102 97.1 108 
Charlson index 3 2 0 3 0 2 1 
 
Table 12. Demographic and clinical data of the “validation cohort” participants 
 Control COPD P Value 
N 26 24  
Age 79 [74.3-80] 78 [71-82.8] 0.95 $ 
Smoking (never/ex/current/NA) 19/4/0/3 1/15/6/2 1 × 10-4 χ 
Smoking pack-year index 0 [0] 40 [30-63.6] 1.2 × 10-6 $ 
FEV1% 115 [100-131.3] 59 [43-81.3] 2.0 × 10-8 t 
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